



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>6</sup> :  C12Q		A2	(11) International Publication Number: <b>WO 99/06587</b>
			(43) International Publication Date: 11 February 1999 (11.02.99)
<p>(21) International Application Number: PCT/EP98/04836</p> <p>(22) International Filing Date: 3 August 1998 (03.08.98)</p> <p>(30) Priority Data: 97113319.4 1 August 1997 (01.08.97) EP</p> <p>(71) Applicant (for all designated States except US): MORPHOSYS GESELLSCHAFT FÜR PROTEINOPTIMIERUNG AG [DE/DE]; Am Klopferspitz 19, D-82152 Martinsried (DE).</p> <p>(72) Inventors; and</p> <p>(75) Inventors/Applicants (for US only): RUDERT, Fritz [DE/DE]; Josef-Retzer-Strasse 36, D-81241 München (DE). GE, Liming [CN/DE]; Portiastrasse 12, D-81545 München (DE). ILAG, Vic [PH/DE]; Knorrstrasse 85, D-89897 München (DE).</p> <p>(74) Agent: VOSSIUS &amp; PARTNER; Siebertstrasse 4, D-81675 München (DE).</p>		<p>(81) Designated States: CA, JP, US, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).</p> <p><b>Published</b> <i>Without international search report and to be republished upon receipt of that report.</i></p>	
<p>(54) Title: NOVEL METHOD AND PHAGE FOR THE IDENTIFICATION OF NUCLEIC ACID SEQUENCES ENCODING MEMBERS OF A MULTIMERIC (POLY)PEPTIDE COMPLEX</p> <div style="display: flex; justify-content: space-around;"> <div style="text-align: center;"> <p>General description of the polyphage principle</p> <p>Diagram illustrating the polyphage principle. It shows two separate libraries, Library 2 and Library 1, each with its own genes (Library 2 gene, Library 1 gene, genell of phage, antibiotic resistance, origin of replication). These genes are combined (a) to form a phage genome. This genome then packages with an origin of replication and antibiotic resistance genes (b) to form a complete phage particle (c). The final phage particle contains genes from both Library 2 and Library 1.</p> </div> <div style="text-align: center;"> <p>General description of the polyphage principle (cont.)</p> <p>Diagram illustrating the polyphage principle (continued). It shows a target being used to select phage particles containing specific genes from Library 1 (d). These selected phage particles are then used to infect host cells (e). The final products are labeled as Note 1 (multimeric) and Note 2 (polymeric), representing the identification of nucleic acid sequences encoding members of a multimeric (poly)peptide complex.</p> </div> </div>			
<p>(57) Abstract</p> <p>The present invention relates to methods for the identification of nucleic acid sequences encoding members of a multimeric (poly)peptide complex by screening for polyphage particles. Furthermore, the invention relates to products and uses thereof for the identification of nucleic acid sequences in accordance with the present invention.</p>			

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Larvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon	KR	Republic of Korea	PL	Poland		
CN	China	KZ	Kazakhstan	PT	Portugal		
CU	Cuba	LC	Saint Lucia	RO	Romania		
CZ	Czech Republic	LI	Liechtenstein	RU	Russian Federation		
DE	Germany	LK	Sri Lanka	SD	Sudan		
DK	Denmark	LR	Liberia	SE	Sweden		
EE	Estonia			SG	Singapore		

**NOVEL METHOD AND PHAGE FOR THE IDENTIFICATION OF NUCLEIC ACID  
SEQUENCES ENCODING MEMBERS OF A MULTIMERIC (POLY)PEPTIDE  
COMPLEX**

The present invention relates to methods for the identification of nucleic acid sequences encoding members of a multimeric (poly)peptide complex by screening for polyphage particles. Furthermore, the invention relates to products and uses thereof for the identification of nucleic acid sequences in accordance with the present invention.

Since its first conception by Ladner in 1988 (WO88/06630), the principle of displaying repertoires of proteins on the surface of phage has experienced a dramatic progress and has resulted in substantial achievements. Initially proposed as display of single-chain Fv (scFv) fragments, the method has been expanded to the display of bovine pancreatic trypsin inhibitor (BPTI) (WO90/02809), human growth hormone (WO92/09690), and of various other proteins including the display of multimeric proteins such as Fab fragments (WO91/17271; WO92/01047).

A Fab fragment consists of a light chain comprising a variable and a constant domain (VL-CL) non-covalently binding to a heavy chain comprising a variable and constant domain (VH-CH1). In Fab display one of the chains is fused to a phage coat protein, and thereby displayed on the phage surface, and the second is expressed in free form, and on contact of both chains, the Fab assembles on the phage surface.

Various formats have been developed to construct and screen Fab phage-display libraries. In its simplest form, just one repertoire, e. g. of heavy chains, is encoded on the phage or phagemid vector. A corresponding light chain, or a repertoire of light chains, is expressed separately. The Fab fragments assemble either inside a host cell, if the light chain is co-expressed from a plasmid, or outside the cell in the medium, if a collection of secreted phage particles each displaying a heavy chain is contacted with the light chain(s) expressed from a different host cell. By screening such Fab libraries, just the information about the heavy chain encoded on the phage or phagemid vector is retrievable, since that vector is packaged in the phage particle. By reverting the format and displaying a library of light chains, and

assembling Fab fragments by co-expressing or adding one or more of the heavy chains identified in the first round, corresponding light chain-heavy chain pairs can be identified.

To avoid that multi-step procedure, both repertoires may be cloned into one phage or phagemid vector, one chain expressible as a fusion with at least part of a phage coat protein, the second expressible in free form. After selection, the phage particle will contain the sequence information about both chains of the selected Fab fragments. The disadvantage of such a format is that the overall complexity of the library is limited by transformation efficiency. Therefore, the library size will usually not exceed  $10^{10}$  members.

For various applications, a library size of up to  $10^{14}$  would be advantageous. Therefore, methods of using site-specific recombination, either based on the Cre/lox system (WO92/20791) or on the att $\lambda$  system (WO 95/21914) have been proposed. Therein, two collection of vectors are sequentially introduced into host cells. By providing the appropriate recombination sites on the individual vectors, recombination between the vectors can be achieved by action of an appropriate recombinase or integrase, achieving a combinatorial library, the overall library size being the product of the sizes of the two individual collections. The disadvantages of the Cre/lox system are that the recombination event is not very efficient, it leads to different products and is reversible. The att $\lambda$  system leads to a defined product, however, it creates one very large plasmid which has a negative impact on the production of phages. Furthermore, the action of recombinase or integrase most likely leads to undesired recombination events.

Thus, the technical problem underlying the present invention is to develop a simple, reliable system which enables the simultaneous identification of members of a multimeric (poly)peptide complex, such as the identification of heavy and light chain of a Fab fragment, in phage display systems.

The solution to this technical problem is achieved by providing the embodiments characterized in the claims. Accordingly, the present invention allows to easily create and screen large libraries of multimeric (poly)peptide complexes for properties such as binding to a target, as in the case of screening Fab fragment libraries, or such as enzymatic activity, as in the case of libraries of multimeric enzymes. The technical approach of the present invention, i.e. the retrieval of information about two members of a multimeric (poly)peptide complex

encoded on two different vectors without requiring a recombination event, is neither provided nor suggested by the prior art.

Accordingly, the present invention relates to a method for identifying a combination of nucleic acid sequences encoding two members of a multimeric (poly)peptide complex with a predetermined property, said combination being contained in a combinatorial library of phage particles displaying a multitude of multimeric (poly)peptides complexes, said method being characterized by screening or selecting for polyphage particles that contain said combination.

Surprisingly, it has been achieved by the present invention that the phenomenon of polyphages can be used to co-package the genetic information of two or more members of multimeric (poly)peptide complexes in a phage display system. The occurrence of polyphage particles has been observed 30 years ago (Salivar et al., *Virology* 32 (1967) 41-51), where it was described that approximately 5% of a phage population form particles which are longer than unit length and which contain two or more copies of phage genomic DNA. They occur naturally when a newly forming phage coat encapsulates two or more single-stranded DNA molecules. In specific cases, it has been seen that co-packaging of phage and phagemids or single-stranded plasmid vectors takes place as well (Russel and Model, *J. Virol.* 63 (1989) 3284-3295). Despite of occasional scientific articles about the morphogenesis of polyphage particles, a practical application has never been discussed or even been mentioned. In WO92/20791 in example 26, a model experiment for a combinatorial Fab display library expressed from separate vectors is presented. However, there is only a screening process for either of the two vectors described. Thus, the prior art teaches away from screening for the simultaneous presence of two vectors in a polyphage particle.

In the context of the present invention, the term "multimeric (poly)peptide complex" refers to a situation where two or more (poly)peptide(s) or protein(s), the "members" of said multimeric complex, can interact to form a complex. The interaction between the individual members will usually be non-covalent, but may be covalent, when post-translational modification such as the formation of disulphide-bonds between any two members occurs. Examples for "multimeric (poly)peptide complexes" comprise structures such as fragments derived from immunoglobulins (e. g. Fv, disulphide-linked Fv (dsFv), Fab fragments), fragments derived from other members of the immunoglobulin superfamily (e.g.  $\alpha, \beta$ -

heterodimer of the T-cell receptor), and fragments derived from homo- or heterodimeric receptors or enzymes. In phage display, one of said members is fused to at least part of a phage coat protein, whereby that member is displayed on, and assembly of the multimeric complex takes place at, the phage surface. A "combinatorial phage library" is produced by randomizing at least two members of said multimeric (poly)peptide complex at least partially on the genetic level to create two libraries of genetically diverse nucleic acid sequences in appropriate vectors, by combining the libraries in appropriate host cells and by achieving co-expression of said at least two libraries in a way that a library of phage particles is produced wherein each particle displays one of the possible combinations out of the two libraries. By screening such a combinatorial phage library displaying multimeric (poly)peptide complexes for a predetermined property, a collection of phage particles will be identified. Partially, these particles will just contain the genetic information of one of the members of the multimeric complex. The inventive principle of the present invention is the screening step for polyphage particles containing the genetic information of a combination of library members.

Furthermore, the present invention relates to a method for identifying a combination of nucleic acid sequences encoding two members of a multimeric (poly)peptide complex with a predetermined property, said combination being contained in a combinatorial library of phage particles displaying a multitude of multimeric (poly)peptides complexes, comprising the steps of

- (a) providing a first library of recombinant vector molecules containing genetically diverse nucleic acid sequences comprising a variety of nucleic acid sequences, each encoding a fusion protein of a first member of a multimeric (poly)peptide complex fused to at least part of a phage coat protein, said fusion protein thereby being able to be directed to, and displayed at, the phage surface, wherein said vector molecules are able to be packaged in a phage particle and carry or encode a first selectable and/or screenable property;
- (b) providing a second library of recombinant vector molecules containing genetically diverse nucleic acid sequences comprising a variety of nucleic acid sequences, each encoding a second member of a multimeric (poly)peptide complex, wherein the vector molecules of said second library are able to be packaged in a phage particle and carry

or encode a second selectable and/or screenable property different from said first property;

- (c) optionally, providing nucleic acid sequences encoding further members of a multimeric (poly)peptide complex;
- (d) expressing members of said libraries of recombinant vectors mentioned in steps (a), (b), and optionally nucleic acid sequences mentioned in step (c), in appropriate host cells under appropriate conditions, so that a combinatorial library of phage particles each displaying a multimeric (poly)peptide complex is produced;
- (e) identifying in said library of phage particles a collection of phages displaying multimeric (poly)peptide complexes having said predetermined property;
- (f) identifying in said collection polyphage particles simultaneously containing recombinant vector molecules encoding a first and a second member of said multimeric (poly)peptide complex by screening or selecting for the simultaneous presence or generation of said first and second selectable and/or screenable property;
- (g) optionally, carrying out further screening and/or selection steps or repeating steps (a) to (f);
- (h) identifying said combination of nucleic acid sequences.

Optionally, further members of said multimeric complex may be provided in the case of ternary, quaternary or higher (poly)peptide complexes. These further members may, for example, be co-expressed from one of the phage or phagemid vectors or from a separate vector such as a plasmid. Even libraries of such further members could be employed in which case further screenable or selectable properties would have to be introduced on the corresponding vectors. Alternatively, such further libraries could be contained in said first or second libraries of recombinant vector molecules. In another option, further screening and/or selection steps or a repetition of the individual steps can be carried out, to optimize the result of obtaining and identifying said nucleic acid sequences.

Furthermore, the present invention relates to a method for identifying a combination of nucleic acid sequences encoding two members of a multimeric (poly)peptide complex with a predetermined property, said combination being contained in a combinatorial library of phage particles displaying a multitude of multimeric (poly)peptides complexes, comprising the steps of

- (a) expressing in appropriate host cells under appropriate conditions

- (aa) genetically diverse nucleic acid sequences contained in a first library of recombinant vector molecules, said nucleic acid sequences comprising a variety of nucleic acid sequences, each encoding a fusion protein of a first member of a multimeric (poly)peptide complex fused to at least part of a phage coat protein, said fusion protein thereby being able to be directed to and displayed at the phage surface, wherein said vector molecules are able to be packaged in a phage particle and carry or encode a first selectable and/or screenable property;
- (ab) genetically diverse nucleic acid sequences contained in a second library of recombinant vector molecules, said nucleic acid sequences comprising a variety of nucleic acid sequences, each encoding a second member of a multimeric (poly)peptide complex, wherein the vector molecules are able to be packaged in a phage particle and carry or encode a second selectable and/or screenable property different from said first property;
- (ac) optionally, nucleic acid sequences encoding further members of a multimeric (poly)peptide complex,  
so that a combinatorial library of phage particles each displaying a multimeric (poly)peptide complex is produced;
- (b) identifying in said library of phage particles a collection of phages displaying multimeric (poly)peptide complexes having said predetermined property;
- (c) identifying in said collection polyphage particles simultaneously containing recombinant vector molecules encoding a first and a second member of said multimeric (poly)peptide complex by screening or selecting for the simultaneous presence or generation of said first and second selectable and/or screenable property;
- (d) optionally, carrying out further screening and/or selection steps or repeating steps (a) to (c);
- (e) identifying said combination of nucleic acid sequences.

In a preferred embodiment of the method of the present invention, the vectors of said first and said second library are a combination of a phage vector and a phagemid vector.

In a further preferred embodiment of the method of the present invention, the vectors of said first and said second library are a combination of two phagemid vectors, said appropriate conditions comprising complementation of phage genes by a helper phage.

In a most preferred embodiment of the method of the present invention said two phagemid vectors are compatible.

The term "compatibility" refers to a property of two phagemids to be able to coexist in a host cell. Incompatibility is connected to the presence of incompatible plasmid origins of replication belonging to the same incompatibility group. An example for compatible plasmid origins of replication is the high-copy number origin ColE1 and the low-copy number origin p15A.

Therefore, in a further preferred embodiment of the method of the present invention, said two phagemid vectors comprise a ColE1 and a p15A plasmid origin of replication.

In a most preferred embodiment of the method of the present invention, said two phagemid vectors comprise a ColE1 and a mutated ColE1 origin.

It could be shown, that two phagemids both having a ColE1-derived plasmid origin of replication can coexist in a cell as long as one of the ColE1 origins carries a mutation.

Particularly preferred is a method, wherein said vectors and/or said helper phage comprise different phage origins of replication.

Most preferred is an embodiment of the method of the present invention, wherein said phage vector, said phagemid vector(s) and/or said helper phage are interference resistant.

The term "interference" refers to a property that phagemids inhibit the production of progeny phage particles by interfering with the replication of the DNA of the phage. "Interference resistance" is a property which overcomes this problem. It has been found that mutations in the intergenic region and/or in gene II contribute to interference resistance (Enea and Zinder, *Virology* 122 (1982), 222-226; Russel et al., *Gene* 45 (1986) 333-338). It was identified that phages called IR1 and IR2 (Enea and Zinder, *Virology* 122 (1982), 222-226), and mutants derived therefrom such as R176 (Russel and Model, *J. Bacteriol.* 154 (1983) 1064-1076), R382, R407 and R408 (Russel et al., *Gene* 45 (1986) 333-338) and R383 (Russel and Model, *J. Virol.* 63 (1989) 3284-3295) are interference resistant by carrying mutations in the untranslated region upstream of gene II and in the gene II coding region.

Therefore, in a preferred embodiment of the method of the present invention, said phage vector, said phagemid vector(s) and/or said helper phage have mutations in the phage intergenic region(s), preferably in positions corresponding to position 5986 of f1, and/or in gene II, preferably in positions corresponding to position 143 of f1.

In a most preferred embodiment said phage vector, said phagemid vector(s) and/or said helper phage are, or are derived from, IR1 mutants such as R176, R382, R383, R407, R408, or from IR2 mutants.

In a further embodiment or the method of the invention, said vectors and/or said helper phage comprise hybrid nucleic acid sequences of f1, fd, and/or M13 derived sequences.

In the context of the present invention, the term "hybrid nucleic sequences" refers to vector elements which comprise sequences originating from different phage(mid) vectors.

Surprisingly, it has been found that a vector constructed combining a part derived from fd phage and a second part derived from R408, a derivative of f1 phages, is interference resistant and additionally, gives predominantly polyphage particles.

Therefore, a most preferred embodiment of the method of the present invention relates to a vector which is, or is derived from, fpep3\_1B-IR3seq with the sequence listed in Figure 4.

In a yet further preferred embodiment of the method according to the present invention, said derivative is a phage comprising essentially the phage origin or replication from fpep3\_1B-IR3seq, the gene II from fpep3\_1B-IR3seq, or a combination of said phage origin of replication and said gene II.

The invention relates in an additional preferred embodiment to a method, wherein said derivative is a phagemid comprising essentially the phage origin or replication from fpep3\_1B-IR3seq, the gene II from fpep3\_1B-IR3seq, or a combination of said phage origin of replication and said gene II.

The invention relates in a further preferred embodiment to a method, wherein said derivative is a helper phage comprising essentially the phage origin or replication from fpep3\_1B-

IR3seq, the gene II from fpep3\_1B-IR3seq, or a combination of said phage origin of replication and said gene II.

Most preferred is an embodiment of the method of the invention, wherein said derivatives comprise the combined fd/f1 origin including the mutation G5737>A (2976 in fpep3\_1B-IR3seq), and/or the mutations G343>A (3989) in gII, and G601>T (4247) in gII/X.

The formation of polyphage particles has been examined in more detail by different groups. It was found that amber mutations in genes VII and IX lead to the amplified production of infectious polyphage particles (Lopez and Webster, *Virology* 127 (1983) 177-193). A couple of mutants in gene VII (R68, R100) and in gene IX (N18) were identified and further characterized.

Accordingly, in a preferred embodiment of the method of the present invention, the gene VII contained in any of said vectors contains an amber mutation, and most preferably, said mutation is identical to those found in phage vectors R68 or R100.

Further preferred is an embodiment, wherein the gene IX contained in any of said vectors contains an amber mutation, and most preferably said mutation is identical to that found in phage vector N18.

Several phage coat proteins have been used in displaying foreign proteins including the gene III protein (gIIIp), gVIp, and gVIIIp.

In a preferred embodiment of the method of the present invention, said phage coat protein is gIIIp or gVIIIp.

In a particularly preferred embodiment of the method of the present invention, said phage particles are infectious by having a full-length copy of gIIIp.

The gIIIp is a protein comprising three domains. The C-terminal domain is responsible for membrane insertion, the two N-terminal domains are responsible for binding to the F pilus of *E. coli* (N2) and for the infection process (N1).

In a most preferred embodiment of the method of the invention, said phage particles are non-infectious by having no full-length copy of gIIIp, said fusion protein being formed with a truncated version of gIIIp, wherein the infectivity can be restored by interaction of the

displayed multimeric (poly)peptide complexes with a corresponding partner coupled to an infectivity-mediating particle.

In the context of the present invention, the term "infectivity-mediating particle" (IMP) refers to a construct comprising either the N1 domain or the N1-N2 domain. On interaction with a non-infectious phage lacking said domains, infectivity of the phage particles can be restored. The interaction between the non-infectious phage and the IMP can be mediated by a ligand fused to the IMP, which can bind to a partner displayed on the phage. By screening a non-infectious phage display library against a target ligand-IMP construct, restoration of infectivity can be used to select target-binding library members.

In a further preferred embodiment of the method of the invention, said truncated gIIIp comprises the C-terminal domain of gIIIp.

In a yet preferred embodiment of the method of the invention, said truncated gIIIp is derived from phage fCA55.

In addition to the work by Lopey and Webster cited above, Crissman and Smith (Virology 132 (1984) 445-455) could show, that the phage fCA55 which has a large deletion in gene III removing the N-terminal domains and a large part of the C-terminal domain leads exclusively to the formation of polyphages.

Particularly preferred is an embodiment of the method of the invention, wherein said predetermined property is binding to a target.

In a preferred embodiment of the method of the invention, said multimeric (poly)peptide complex is a fragment of an immunoglobulin superfamily member.

In a most preferred embodiment of the method of the invention, said multimeric (poly)peptide complex is a fragment of an immunoglobulin.

In a further most preferred embodiment of the method of the invention, said fragment is an Fv, dsFv or Fab fragment.

An additional preferred embodiment of the present invention relates to a method, wherein said predetermined property is the activity to perform or to catalyze a reaction.

In a preferred embodiment of the method of the invention, said multimeric (poly)peptide complex is an enzyme.

In a most preferred embodiment of the method of the invention, said multimeric (poly)peptide complex is a fragment of a catalytic antibody.

In a further most preferred embodiment of the method of the invention, said fragment is an Fv, dsFv or Fab fragment.

An additional preferred embodiment of the invention relates to a method, wherein selectable and/or screenable property is the transactivation of transcription of a reporter gene such as beta-galactosidase, alkaline phosphatase or nutritional markers such as his3 and leu, or resistance genes giving resistance to an antibiotic such as ampicillin, chloramphenicol, kanamycin, zeocin, neomycin, tetracycline or streptomycin.

In a most preferred embodiment of the method of the invention, said generation of said first and second screenable and/or selectable property is achieved after infection of appropriate host cells by said collection of phage particles.

Particularly preferred is a method, wherein said identification of said nucleic acid sequences is effected by sequencing.

Further preferred is a method, wherein said host cells are E.coli XL-1 Blue, K91 or derivatives, TG1, XL1kann or TOP10F.

An additional preferred embodiment of the invention relates to a polyphage particle which

(a) contains

(i) a first recombinant vector molecule that comprises a nucleic acid sequence, which encodes a fusion protein of a first member of a multimeric (poly)peptide complex

fused to at least part of a phage coat protein, and that carries or encodes a first selectable and/or screenable property, and

(ii) a second recombinant vector molecule that comprises a nucleic acid sequence, which encodes a second member of a multimeric (poly)peptide complex, and that carries or encodes a second selectable and/or screenable property different from said first property;

and (b) displays said multimeric (poly)peptide complex at its surface.

A most preferred embodiment of the invention relates to a polyphage particle, wherein said phage coat protein is the gIIIp.

A further preferred embodiment of the present invention relates to a polyphage particle which is infectious by having a full-length copy of gIIIp present, either in said fusion protein, or in an additional wild-type copy.

Additionally, the invention relates to a polyphage particle which is non-infectious by having no full-length copy of gIIIp, said fusion protein being formed with a truncated version of gIIIp, wherein the infectivity can be restored by interaction of the displayed multimeric (poly)peptide complex with a corresponding partner coupled to an infectivity-mediating particle.

Most preferably, the invention relates to the phage vector fpep3\_1B-IR3seq with the sequence listed in Figure 4.

Additionally preferred, the invention relates to a phage vector derived from phage vector fpep3\_1B-IR3seq comprising essentially the phage origin or replication from fpep3\_1B-IR3seq, the gene II from fpep3\_1B-IR3seq, or a combination of said phage origin of replication and said gene II.

Further preferred is an embodiment of the invention, which relates to a phagemid vector derived from phage vector fpep3\_1B-IR3seq comprising essentially the phage origin or replication from fpep3\_1B-IR3seq, the gene II from fpep3\_1B-IR3seq, or a combination of said phage origin of replication and said gene II.

Preferably, the invention relates to a helper phage vector derived from phage vector fpep3\_1B-IR3seq comprising essentially the phage origin or replication from fpep3\_1B-IR3seq, the gene II from fpep3\_1B-IR3seq, or a combination of said phage origin of replication and said gene II.

Additionally preferred is an embodiment, said derivatives comprise the combined fd/f1 origin including the mutation G5737>A (2976 in fpep3\_1B-IR3seq), and/or the mutations G343>A (3989) in gII, and G601>T (4247) in gII/X.

Further preferred is the use of any of the vectors according to the present invention in the generation of polyphage particles containing a combination of at least two different vectors.

Most preferred is the use of vectors of the invention, wherein said combination of different vectors comprises nucleic acid sequences encoding members of a multimeric (poly)peptide complex.

Further preferred in the present invention is the use of vectors, wherein said combination of different vectors comprises nucleic acid sequences encoding interacting (poly)peptides/proteins.

#### Legends to Figures:

**Figure 1:** General description of the polyphage principle for the display of a Fab library:  
e.g. library 1: library of VL chains; library 2: VH chains; both libraries on compatible phagemids; in a: libraries are transformed into host cells; in b: library 1 is rescued by a helper phage; in c: libraries are combined by infection; in d: co-expression of heavy and light chains; in e: rescue by helper phages, production of phage particles, assembly of Fab on phage, selection for target; note 1: A certain fraction of the phage particles will be normal unit-length particles containing just one of the two genomes (not shown in Figure 1). Furthermore, polyphage does not discriminate which genomes to package. Therefore, the combinations shown in Figure 1 can arise. To select for

correctly packaged genomes, the subsequent steps are required; in f: infect host cells; in g: select for ability to confer resistance to two antibiotics to infected cells; note 2: only phage that satisfy condition according to g) represent polyphage particles which contain the correct combination of heavy and light chain of binding Fabs (Hetero-polyphage). Unit-length phage as well as polyphage carrying two identical genomes will confer only resistance to one antibiotics.

**Figure 2:** Functional map and sequence of phage vector ftag1A

**Figure 3:** Functional map and sequence of phage vector fjun\_1B

**Figure 4:** Functional map and sequence of phage vector fpep3\_1B-IR3seq

**Figure 5:** Compatibility of various phage and phagemid vectors: co-transformation of different vector pairs and growth in liquid culture (can/amp selection):  
A. fjun\_1B-R408-IR/pIG10\_pep10; B. fjun\_1B/pIG10\_pep10 (only 1 colony);  
C. fpep3\_1B-IR3/pIG10\_pep10; D. fjun\_1B-R408-IR/pOK1Djun; E. fjun\_1B/pOK1Djun: no growth; F. fpep3\_1B-IR3/pOK1Djun;  
a. fjun\_1B; b. fjun\_1B-R408-IR; c. fpep3\_1B-IR3; d. pIG10\_pep10; e. pOK1Djun

**Figure 6:** co-transformation of positive (pep3/p75ICD combination, lane 9) and negative (jun/p75ICD, lane 10) pairs; lane 1 to 8: SIP transductants

**Figure 7:** Sensitivity of SIP hetero-polyphage system for selection in solution: #SIP hetero-polyphage transductants, transducing units (t.u.)/ml, produced by co-cultures of co-transformants as in Figure 6 mixed at the indicated ratios.

**Figure 8:** PCR to identify phage vector(s) present in SIP polyphage transductants: lane 1 to 6: SIP polyphage transductants; lane A: fpep3\_1B-IR3/pIG10.3-IMPP75 co-transformant; lane B: fjun\_1B-IR3/pIG10.3-IMPP75 co-transformant

**Figure 9:** IR Phage and Phagemid are Co-packaged into Polyphages: 1:  $\Delta$ gIII phage + gIII plasmid; 2: IR phage+ phagemid

**Figure 10:** SIP Information is Co-transduced by Polyphages: a: IMPP75 on phage vector; b: pep10-gIII-CT fusion on phage vector; c: IMPP75 on phagemid vector; d: pep10-gIII-CT fusion on phagemid vector

The examples illustrate the invention

### **Example 1: Selection for polyphage transductants**

In WO92/01047, page 83, a model experiment for a two-vector system is described which uses a phage vector (fd-CAT2-IV) encoding a light chain and a phagemid vector (pHEN1-III) encoding a heavy chain. The phagemid, grown in *E. coli* HB2151, was rescued with fd-CAT2-IV phage, and functional phage(mid)s produced. By infecting TG1 cells and plating on tetracycline (to select for fd-CAT) and ampicillin (to select for pHEN1), the ratio of phage and phagemid being packaged was determined.

By repeating this experiment, but plating on TYE plates with both antibiotics, polyphage transductants transducing both resistances simultaneously can be selected, and the genetic information contained on the phage and phagemid vector can be retrieved.

By replacing the single light and heavy chain in the constructs mentioned above by corresponding repertoires, a library of Fab-displaying phage particles can be produced. By screening that library against an immobilized target, a collection of phage particles can be identified. Polyphage particles contained in that collection can be identified by transducing both resistances as described above.

### **Example 2: Generation and use of an interference-resistant filamentous phage to co-package the genetic information of co-displayed interacting proteins**

#### **Introduction**

The physical connection of randomly combined genetic information is of vital importance in processes such as interactive screening of two libraries of expressed protein members or for co-expression and co-display of protein pairs which are dependent on the interaction with each other for proper function.

#### **2.1.: Construction of a interference resistant filamentous phage:**

##### **2.1.1.: Construction of fjun\_1B:**

###### **- ftag1A (see Figure 2)**

- a. The phage vector f17/9-hag (Krebber *et al.*, 1995, *FEBS Letters* 377, 227-231) is digested with EcoRV and XmnI. The 1.1 kb fragment containing the anti-HAG Ab gene is isolated

by agarose gel electrophoresis and purified with a Qiagen gel extraction kit. This fragment is ligated into a pre-digested pIG10.3 vector (EcoRV-XmnI). Ligated DNA is transformed into DH5 $\alpha$  cells and positive clones are verified by restriction analysis. The recombinant clone is called pIGhag1A. All cloning described above and subsequently are according to standard protocols (Sambrook *et al.*, 1989, *Molecular Cloning: a Laboratory Manual*, 2<sup>nd</sup> ed.)

- b. The vector f17/9-hag (Krebber *et al.*, 1995) is digested with EcoRV and StuI. The 7.9 kb fragment is isolated and self-ligated to form the vector ftag2.
- c. The chloramphenicol resistance gene (CAT) assembled *via* assembly PCR (Ge and Rudolph, *BioTechniques* 22 (1997) 28-29) using the template pACYC (Cardoso and Schwarz, *J. Appl. Bacteriol.* 72 (1992) 289-293) is amplified by the polymerase chain reaction (PCR) with the primers:

CAT\_BspEI(for): 5' GAATGCTCATCCGGAGTTC

CAT\_Bsu36I(rev): 5' TTTCACTGGCCTCAGGCTAGCACCAGGCCTTAAG

- d. The PCR is done following standard protocols (Sambrook *et al.*, 1989). The amplified product is digested with BspEI and Bsu36I then ligated into pre-digested ftag2 vector (BspEI-Bsu36I; 7.2 kb fragment) to form ftag2C.
- e. The vector ftag2C is digested with EcoRI and the ends made blunt by filling-in with Klenow fragment. The flushed vector is self-ligated to form vector ftag2CdelEcoRI.
- f. pIGhag1A is digested with XbaI and HindIII. The 1.3 kb fragment containing the anti-HAG gene fused with the C-terminal domain of filamentous phage pIII protein is isolated and ligated with a pre-digested ftag2CdelEcoRI phage vector (XbaI-HindIII; 6.4 kb) to create the vector ftag1A.

- fjun\_1B (see Figure 3)

- a. The DNA encoding the C-terminal domain including the long linker separating it from the amino terminal domain of the filamentous phage pIII (gIII short) is amplified by PCR using pOK1 (Gramatikoff *et al.*, *Nucleic Acids Res.* 22 (1994) 5761-5762) as template with the primers:

gIII short(for): 5'GCTTCCGGAGAATTCAATGCTGGCGGGCTCT3'

gIII short(rev): 5'CCCCCCCCAAGCTTATCAAGACTCCTTATTACG3'

- b. The PCR is done following standard protocols (Sambrook *et al.*, 1989). The amplified product is digested with EcoRI and HindIII, then ligated into pre-digested ftag1A vector (EcoRI-HindIII) to form the vector fjun\_1B.

**2.1.2.: Construction of fjun\_1B-R408IR:**

In order to introduce mutations which have been described to confer an interference resistance phenotype (Enea and Zinder, *Virology* 122 (1982), 222-226) into the non-interference resistant fd phage vector fjun\_1B (see Fig.3), a 1.7 kb fragment of helper phage R408 (Stratagene) comprising the region between the unique restriction sites *Dra*III and *Bsr*GI was PCR amplified by assembly PCR. Subfragments of the 1.7 kb *Dra*III/*Bsr*GI fragment were amplified from the f1 phage R408 template DNA with primer combinations FR604/FR605 and FR606/FR607 to introduce via the partially complementary primers FR605 and FR606 an additional gII mutation found to be present in the recipient construct fjun\_1B. Resulting PCR fragments were gel-purified and combined to serve as template in an subsequent assembly PCR with primers FR604 and FR607. PCR conditions were standard, with approx. 25 ng template, 10 pmole of each primer, 250 pmole of each dNTP, 2 mM Mg, 2.5 U Pfu DNA polymerase (Stratagene). Amplification was done for 30 cycles, with 1 min denaturation at 94°C, 1 min annealing at 50°C, 1 min extension at 72°C. The correct-sized 1.7 kb assembly PCR product was gel-purified, digested with *Dra*III and *Bsr*GI and cloned into *Dra*III/*Bsr*GI-digested fjun\_1B, generating fjun\_1B-R408IR.

Primers: FR604 5' GTTCACGTAGTGGGCCATCG 3'  
FR605 5' TGAGAGGTCTAAAAAGGCTATCAGG 3'  
FR606 5' TAGCCTTTAGACCTCTAAAAATAG 3'  
FR607 5' CGGTGTACAGACCAGGCGC 3'

**2.2.: Proof of principle experiments**

Despite of the absence of the two originally associated IR mutations, the hybrid phage vector fjun\_1B-R408IR (carrying the chloramphenicol acetyltransferase conferring chloramphenicol resistance) could be co-transformed with a phagemid (pOK1deltajun, carrying the beta-lactamase gene conferring ampicillin resistance) containing a phage origin of replication. More importantly, fjun\_1B-R408IR could stably co-exist with the phagemid pOK1deltajun, and the phagemid was efficiently co-packaged together with the fjun\_1B-R408IR phage genome into polyphage particles. Titers of polyphages, simultaneously

transducing chloramphenicol and ampicillin resistance, reached  $6 \times 10^8$  transducing units (t.u.)/ml of overnight bacterial culture K91 plating cells, a number almost equivalent to a titer of  $10^9$ /ml seen after selection on chloramphenicol only. Selection of the K91 transductants on ampicillin only gave a titer of  $5 \times 10^9$ /ml. These titers indicated that more than 50 % of all phages containing fjun\_1B-R408IR also contained the phagemid pOK1deltajun, thus representing polyphages. This high ratio of polyphages was confirmed by restriction analysis of transductants which had been selected on chloramphenicol only. More than 50 % of these clones also contained the phagemid in addition to the fjun\_1B-R408IR phage genome. fjun\_1B-R408IR was isolated in pure form from an individual transductant, which contained only this phage. The construct fjun\_1B-R408IR was used with pOK1deltajun for co-transformation of DH5 $\alpha$  cells, in order to produce selectively-infective phages (SIP) via fos-jun leucine zipper interaction (which non-covalently restores wt gIII function). Stable, double-resistant co-transformants were obtained with this combination and individual clones were grown overnight in the presence of cam/amp. The culture supernatant of these clones was filtered through a 45  $\mu$ M membrane filter and used to infect exponentially-growing F+ bacteria (K91 strain) for 20 min at 37 C. To test for the presence of infective SIP polyphages the cells were plated on LB agar plates containing cam and amp and plates were incubated at 37 C overnight. Approx. 500 to 1000 transforming units (t.u.)/ml resulting in double-resistant transductants were obtained from individual co-transformants. DNA of those transductants was analyzed by restriction analysis which showed that 95 % (15/16 clones) of the clones had the correct pattern expected for fjun\_1B-R408IR and pOK1deltajun. Supernatants of several polyphage transductants were tested for persistent SIP phage production by re-infection of K91 cells. This confirmed that polyphage transductants continued to produce infective SIP phages and restriction analysis of the resulting 2<sup>nd</sup> round polyphage transductants showed that 44 % (14/32 clones) contained the correct vector combination. The rest of the clones contained the correct pOK1deltajun phagemid plus a recombined phage vector with a restored wt gIII, indicating an increase in recombination frequency when both vectors are propagated in the rec+ strain K91 (compared to the rec- strain DH5 $\alpha$  used for co-transformation of IR phage and phagemid). To test other protein-protein interactions which give a higher titer of infective SIP phages and to verify the presence of hetero-polyphages (co-packaging of phage and phagemid instead of co-infection by monophages or homo-polyphages), two peptide ligands (previously selected by SIP, WO97/32017)

which bind to the p75 rat neurotrophin receptor (Chao et al., *Science* 232 (1986) 518-521) intracellular domain (p75ICD) were cloned as N-terminal gIIIc fusions in fjun\_1B-R408IR (replacing jun) and the phagemid pIG10.3, leading to constructs fpep3\_1B-IR3seq and pIG10.3-pep10 (WO97/32017), respectively, which contain the peptide pep3: 5'-TGTATTGTTATCATGCTCATTATCTTGTGCTAAGTGT-3' encoding the amino acid sequence (CysIleValTyrHisAlaHisTyrLeuValAlaLysCys) instead of the jun sequence. Sequencing of the respective parts of the transferred R408 fragment in fpep3\_1B-IR3seq revealed that neither of the two IR mutations (the G5986>A mutation from complementation group I in the gII 5' non-translated region, which should be found at position 3225 in fpep3\_1B-IR3seq, and the C143>T mutation (3789 in fpep3\_1B-IR3seq) from complementation group II leading to a Thr>Ile amino acid exchange in gII) were found to be present. However, the gII mutation G6090>T (3329 in fpep3\_1B-IR3seq), leading to a Leu>Val exchange, introduced by assembly PCR was present. Furthermore, three additional mutations compared to an f1 phage could be identified: G5737>A (2976 in fpep3\_1B-IR3seq) in the phage origin of replication, G343>A (3989) in gII, and G601>T (4247) in gII/X.

The functional map and the sequence of fpep3\_1B-IR3seq are given in Figure 4. This sequence was double-checked several times. It could be shown that differences in the sequence of fpep3\_1B-IR3seq compared to published sequence data could be explained by mutations already present in the starting constructs used for cloning fjun\_1B-R408IR and fpep3\_1B-IR3seq.

Co-transformation experiments (Fig. 5) using combinations of pIG10.3 or pOK1 phagemids (both with f1 oris) with fjun\_1B ("wt" fd phage), fjun\_1B-R408-IR (containing the DraIII/BsrGI fragment from R408) or fpep3\_1B-IR3 (containing the DraIII/BsrGI fragment from R408 and the PCR mutation) revealed that the PCR mutation is not necessary for the IR phenotype, at least judged by the ability to be co-transformable with a phagemid and the ability of individual co-transformants to grow in liquid culture (cam/amp selection).

Additionally, the interacting protein partner p75ICD was cloned as a C-terminal fusion to the infectivity-mediating domains (N1-N2) of gIII (infectivity-mediating particle (IMP) fusion) resulting in constructs fIMPP75-IR3 and pIG10.3-IMPP75.

The IR phage was tested with the SIP pairing fpep3\_1B-IR3seq3/ pIG10.3-IMPP75 (which gives a higher titer than fos/jun SIP) in the presence of the negative control combination fjun\_1B-IR3seq3/ pIG10.3-IMPP75 (Fig. 6). A SIP hetero-polyphage titer of  $1.5 \times 10^5$ /ml (cam/amp-resistant transductants) was achieved with fpep3\_1B-IR3seq3/ pIG10.3-IMPP75. To test SIP sensitivity in a model library vs. library setting, co-transformants of fpep3\_1B-IR3seq3/ pIG10.3-IMPP75 were diluted in an excess fjun\_1B-IR3/ pIG10.3-IMPP75 and the supernatant of the bacterial co-culture was assayed for SIP hetero-polyphages. This showed that down to a dilution of  $10^{-5}$  to  $10^{-6}$  can be recovered (Fig. 7).

To prove that only the correct phage vector is present in SIP polyphage transductants, DNA of positive (fpep3\_1B-IR3seq3/ pIG10.3-IMPP75) and negative (fjun\_1B-IR3/ pIG10.3-IMPP75) control co-transformants, as well as DNA from the SIP polyphage transductants derived from SIP phages produced by the mix of positive and negative control bacteria was analyzed by PCR (Fig. 8). Primers FR614 (5'-GCTCTAGATAACGAGGGC-3') and FR627 (5'-CGCAAGCTTAAGACTCCT-TATTACGC-3') amplify the phage region from the start of ompA to the end of gIII. PCR products derived from fpep3\_1B-IR3seq3 and fjun\_1B-IR3 can be discriminated by size. Gel analysis of the above samples verified that only the expected fpep3\_1B-IR3seq3 phage was present in SIP polyphage transductants (6 analyzed).

To physically demonstrate the existence of hetero-polyphages (which have phage and phagemid co-packaged) when using the IR phage vector, phages produced by co-transformants of fIR3/pIG10.3-IMPP75 and as a control fjun\_1B/JB61 ("wt" phage plus complementing gIII plasmid) were separated on an agarose gel (Fig. 9). This showed that the fIR3/pIG10.3-IMPP75 combination produced substantially more slower migrating (thus bigger) phages than the fjun\_1B/JB61 control combination. The ratio was almost inverted. Elution of phages from various regions of the gel and subsequent titering of the eluate on plating cells showed that the upper gel region contained a significant portion of double resistance-transducing phages which thus can be regarded as hetero-polyphages.

The pairs fpep3\_1B-IR3 and pIG10.3-IMPP75 as well as fIMPP75-IR3 and pIG10.3-pep10 were co-transformed into DH5 $\alpha$ , individual cam/amp resistant clones were grown and the culture supernatant was tested on K91 cells for SIP phage production (Fig. 10). The combinations fpep3\_1B-IR3/pIG10.3-IMPP75 and fIMPP75-IR3/pIG10.3-pep10 gave a titer of  $1.5 \times 10^5$  t.u./ml and  $5 \times 10^3$  t.u./ml, respectively when assayed for cam/amp-resistant transductants. The titer for each combination when assayed on LB cam was nearly the same as when assayed on LB cam/amp. This demonstrated efficient co-packaging of phage and phagemid DNA to almost 100 %, as seen before with the initial fjun\_1B-R408IR and pOK1deltajun combination. To proof the existence of polyphages which individually co-transduce phage and phagemid DNA simultaneously, and to rule out the possibility of transduction of the two resistance markers by independent (and thus random) co-infection by two different phages which have only phage or phagemid packaged, a statistical test was performed. Defined, identical aliquots of bacterial culture supernatants of an individual co-transformant representing each of the two SIP vector combinations described above (fpep3\_1B-IR3/pIG10.3-IMPP75 and fIMPP75-IR3/pIG10.3-pep10) were either used individually to infect K91 cells followed by selection on LB cam and LB amp plates, or the same supernatant aliquots from the two vector combinations were mixed before infection of K91 cells and selection on LB cam/amp. 117 cam-resistant, 328 amp-resistant and 141 cam/amp-resistant transforming units were present in the supernatant aliquot from the fIMPP75-IR3/pIG10.3-pep10 combination and 40 cam-resistant, 30 amp-resistant and 23 cam/amp-resistant transforming units were present in the supernatant aliquot from the fpep3\_1B-IR3/pIG10.3-IMPP75 combination. The mix of both supernatant aliquots contained 166 cam-resistant and 162 cam/amp-resistant transforming units, exactly corresponding to the expected numbers which would be obtained by adding up the transducing units of the two individual aliquots. 48 cam/amp-resistant transductant colonies were picked from the plate were the mix of the two individual aliquots was used for infection and were analyzed by restriction digest. This showed that only the correct, SIP phage-producing vector combination (5 clones containing the fpep3\_1B-IR3/pIG10.3-IMPP75 and 43 clones containing the fIMPP75-IR3/pIG10.3-pep10 combination; this represents a ratio of the two input vector combinations in the analyzed transductants of 1 : 8.6 (fpep3\_1B-IR3/pIG10.3-IMPP75 : fIMPP75-IR3/pIG10.3-pep10), which is very similar to the 1 : 6.1 (fpep3\_1B-IR3/pIG10.3-IMPP75 : fIMPP75-IR3/pIG10.3-pep10) ratio of double-resistant input phages in this experiment) occurred in all analyzed

transductants, verifying the presence of hetero-polyphages by ruling out the possibility of random co-infection and thus incorrect, random combination by two out of four possible monophage and/or homo-polyphage populations (fpep3\_1B-IR3, pIG10.3-IMPP75, fIMPP75-IR3 and pIG10.3-pep10) each containing only one type of vector (phage or phagemid). Statistically, co-infection of the same bacterium by two separate phages was practically already excluded by the small numbers of infective phages containing at least one resistance marker (166 cam-resistant and 358 amp-resistant phages) which were used in the above experiment. Co-infection of the same bacterium (of a total of  $10^7$  bacteria) by one of the 166 cam-resistant phages and one of the 358 amp-resistant phages has a probability of  $6 \times 10^{-10}$ . Moreover, in this scenario incorrect combinations of individual phage and phagemid vectors (e.g. fpep3\_1B-IR3/ pIG10.3-pep10 and fIMPP75-IR3/ pIG10.3-IMPP75) would be possible. The fact that only the correct vector combinations were found in all 48 transductants analyzed from this experiment further proved that co-transduction by hetero-polyphage and not random co-infection by homo-polyphage or monophage was the mechanism by which double-resistance was transduced.

### **2.3.: Construction of a phage-display system for Fab display**

The constructs described in 3.2. can easily be modified to achieve the display of Fabs or a Fab library. In fpep3\_1B-IR3seq, the jun part can be replaced by a VL-CL light chain repertoire having the appropriate 3'- and 5'-restriction sites similarly as described for pep\_3-to construct fVL\_1B-R408IR. In pIG10.3-IMPP75, the IMPP75 construct can be replaced by a repertoire of VH-CH1 heavy chains. After co-transformation of both repertoires into host cells and expression, a library of phage particles displaying Fab fragments is produced. Since fpep3\_1B-IR3seq was set up for a SIP experiment by having just the C-terminal domain of gIII, the corresponding Fab-displaying phage particles are non-infectious. By adding a target molecule fused to an infectivity-mediating particle (N1-N2 domain of gIIIp), phages displaying target-binding Fab fragments can be selected by infecting host cells.

By replacing the truncated gIII part described above by a full-length copy of gIII, a Fab-display library of infectious phage particles is obtained, which can be screened against immobilized targets. Binding phages can be eluted and used to infect host cells.

By selecting for transductants conferring cam/amp-resistance to their host cells, polyphage infections can be selected in both cases. Thereby the information about both chains of the selected Fab fragments can be retrieved.

## CLAIMS

1. A method for identifying a combination of nucleic acid sequences encoding two members of a multimeric (poly)peptide complex with a predetermined property, said combination being contained in a combinatorial library of phage particles displaying a multitude of multimeric (poly)peptides complexes, said method being characterized by screening or selecting for polyphage particles that contain said combination.
2. The method of claim 1, comprising the steps of
  - (a) providing a first library of recombinant vector molecules containing genetically diverse nucleic acid sequences comprising a variety of nucleic acid sequences, each encoding a fusion protein of a first member of a multimeric (poly)peptide complex fused to at least part of a phage coat protein, said fusion protein thereby being able to be directed to, and displayed at, the phage surface, wherein said vector molecules are able to be packaged in a phage particle and carry or encode a first selectable and/or screenable property;
  - (b) providing a second library of recombinant vector molecules containing genetically diverse nucleic acid sequences comprising a variety of nucleic acid sequences, each encoding a second member of a multimeric (poly)peptide complex, wherein the vector molecules of said second library are able to be packaged in a phage particle and carry or encode a second selectable and/or screenable property different from said first property;
  - (c) optionally, providing nucleic acid sequences encoding further members of a multimeric (poly)peptide complex;
  - (d) expressing members of said libraries of recombinant vectors mentioned in steps (a), (b), and optionally nucleic acid sequences mentioned in step (c), in appropriate host cells under appropriate conditions, so that a combinatorial library of phage particles each displaying a multimeric (poly)peptide complex is produced;
  - (e) identifying in said library of phage particles a collection of phages displaying multimeric (poly)peptide complexes having said predetermined property;
  - (f) identifying in said collection polyphage particles simultaneously containing recombinant vector molecules encoding a first and a second member of said

multimeric (poly)peptide complex by screening or selecting for the simultaneous presence or generation of said first and second selectable and/or screenable property;

(g) optionally, carrying out further screening and/or selection steps or repeating steps (a) to (f);

(h) identifying said combination of nucleic acid sequences.

3. The method of claim 1, comprising the steps of

(a) expressing in appropriate host cells under appropriate conditions

(aa) genetically diverse nucleic acid sequences contained in a first library of recombinant vector molecules, said nucleic acid sequences comprising a variety of nucleic acid sequences, each encoding a fusion protein of a first member of a multimeric (poly)peptide complex fused to at least part of a phage coat protein, said fusion protein thereby being able to be directed to and displayed at the phage surface, wherein said vector molecules are able to be packaged in a phage particle and carry or encode a first selectable and/or screenable property;

(ab) genetically diverse nucleic acid sequences contained in a second library of recombinant vector molecules, said nucleic acid sequences comprising a variety of nucleic acid sequences, each encoding a second member of a multimeric (poly)peptide complex, wherein the vector molecules are able to be packaged in a phage particle and carry or encode a second selectable and/or screenable property different from said first property;

(ac) optionally, nucleic acid sequences encoding further members of a multimeric (poly)peptide complex,

so that a combinatorial library of phage particles each displaying a multimeric (poly)peptide complex is produced;

(b) identifying in said library of phage particles a collection of phages displaying multimeric (poly)peptide complexes having said predetermined property;

(c) identifying in said collection polyphage particles simultaneously containing recombinant vector molecules encoding a first and a second member of said multimeric (poly)peptide complex by screening or selecting for the simultaneous presence or generation of said first and second selectable and/or screenable property;

- (d) optionally, carrying out further screening and/or selection steps or repeating steps (a) to (c);
- (e) identifying said combination of nucleic acid sequences.

4. The method of anyone of claims 1 to 3, wherein the vectors of said first and said second library are a combination of a phage vector and a phagemid vector.
5. The method of anyone of claims 1 to 3, wherein the vectors of said first and said second library are a combination of two phagemid vectors, said appropriate conditions comprising complementation of phage genes by a helper phage.
6. The method of claim 5, wherein said two phagemid vectors are compatible.
7. The method of claim 6, wherein said two phagemid vectors comprise a ColE1 and a p15A plasmid origin of replication.
8. The method of claim 6, wherein said two phagemid vectors comprise a ColE1 and a mutated ColE1 origin.
9. The method of anyone of claims 4 to 8, wherein said vectors and/or said helper phage comprise different phage origins of replication.
10. The method of anyone of claim 4 to 9, wherein said phage vector, said phagemid vector(s) and/or said helper phage are interference resistant.
11. The method of claim 10, wherein said phage vector, said phagemid vector(s) and/or said helper phage have mutations in the phage intergenic region(s), preferably in positions corresponding to position 5986 of f1, and/or in gene II, preferably in positions corresponding to position 143 of f1.
12. The method of anyone of claims 10 to 11, wherein said phage vector, said phagemid vector(s) and/or said helper phage are, or are derived from, IR1 mutants such as R176, R382, R383, R407, R408, or from IR2 mutants.

13. The method of anyone of claims 4 to 11, wherein said vectors and/or said helper phage comprise hybrid nucleic acid sequences of f1, fd, and/or M13 derived sequences.
14. The method of anyone of claims 1 to 13, wherein said vector is, or is derived from, fpep3\_1B-IR3seq with the sequence listed in Figure 4.
15. The method of claim 14, wherein said derivative is a phage comprising essentially the phage origin of replication from fpep3\_1B-IR3seq, the gene II from fpep3\_1B-IR3seq, or a combination of said phage origin of replication and said gene II.
16. The method of claim 14, wherein said derivative is a phagemid comprising essentially the phage origin of replication from fpep3\_1B-IR3seq, the gene II from fpep3\_1B-IR3seq, or a combination of said phage origin of replication and said gene II.
17. The method of claim 14, wherein said derivative is a helper phage comprising essentially the phage origin of replication from fpep3\_1B-IR3seq, the gene II from fpep3\_1B-IR3seq, or a combination of said phage origin of replication and said gene II.
18. The method of anyone of claims 15 to 17, said derivatives comprise the combined fd/f1 origin including the mutation G5737>A (2976 in fpep3\_1B-IR3seq), and/or the mutations G343>A (3989) in gII, and G601>T (4247) in gII/X.
19. The method of anyone of claims 1 to 18, wherein the gene VII contained in any of said vectors contains an amber mutation.
20. The method of claim 19, wherein said mutation is identical to those found in phage vectors R68 or R100.
21. The method of anyone of claims 1 to 20, wherein the gene IX contained in any of said vectors contains an amber mutation.

22. The method of claim 21, wherein said mutation is identical to that found in phage vector N18.
23. The method of anyone of claims 1 to 22, wherein said phage coat protein is gIIIp or gVIIIp.
24. The method of anyone of claims 1 to 23, wherein said phage particles are infectious by having a full-length copy of gIIIp.
25. The method of anyone of claims 1 to 24, wherein said phage particles are non-infectious by having no full-length copy of gIIIp, said fusion protein being formed with a truncated version of gIIIp, wherein the infectivity can be restored by interaction of the displayed multimeric (poly)peptide complexes with a corresponding partner coupled to an infectivity-mediating particle.
26. The method of claim 25, wherein said truncated gIIIp comprises the C-terminal domain of gIIIp.
27. The method of claim 26, wherein said truncated gIIIp is derived from phage fCA55.
28. The method of anyone of claims 1 to 27, wherein said predetermined property is binding to a target.
29. The method of claim 28, wherein said multimeric (poly)peptide complex is a fragment of an immunoglobulin superfamily member.
30. The method of claim 29, wherein said multimeric (poly)peptide complex is a fragment of an immunoglobulin.
31. The method of claim 30, wherein said fragment is an Fv, dsFv or Fab fragment.
32. The method of anyone of claims 1 to 27, wherein said predetermined property is the activity to perform or to catalyze a reaction.

33. The method of claim 32, wherein said multimeric (poly)peptide complex is an enzyme.
34. The method of claim 33, wherein said multimeric (poly)peptide complex is a fragment of a catalytic antibody.
35. The method of claim 34, wherein said fragment is an Fv, dsFv or Fab fragment.
36. The method of anyone of claims 1 to 35, wherein said selectable and/or screenable property is the transactivation of transcription of a reporter gene such as beta-galactosidase, alkaline phosphatase or nutritional markers such as his3 and leu, or resistance genes giving resistance to an antibiotic such as ampicillin, chloramphenicol, kanamycin, zeocin, neomycin, tetracycline or streptomycin.
37. The method of anyone of claims 1 to 36, wherein said generation of said first and second screenable and/or selectable property is achieved after infection of appropriate host cells by said collection of phage particles.
38. The method of anyone of claims 1 to 37, wherein said identification of said nucleic acid sequences is effected by sequencing.
39. The method of anyone of claims 1 to 38, wherein said host cells are E.coli XL-1 Blue, K91 or derivatives thereof, TG1, XL1kann or TOP10F.
40. A polyphage particle which
  - (a) contains
    - (i) a first recombinant vector molecule that comprises a nucleic acid sequence, which encodes a fusion protein of a first member of a multimeric (poly)peptide complex fused to at least part of a phage coat protein, and that carries or encodes a first selectable and/or screenable property, and
    - (ii) a second recombinant vector molecule that comprises a nucleic acid sequence, which encodes a second member of a multimeric (poly)peptide complex, and that

carries or encodes a second selectable and/or screenable property different from said first property;

and (b) displays said multimeric (poly)peptide complex at its surface.

41. The polyphage particle according to claim 40 wherein said phage coat protein is the gIIIp.

42. The polyphage particle according to claim 41 wherein said particles is infectious by having a full-length copy of gIIIp present, either in said fusion protein, or in an additional wild-type copy.

43. The polyphage particle according to claim 41 wherein said particles is non-infectious by having no full-length copy of gIIIp, said fusion protein being formed with a truncated version of gIIIp, wherein the infectivity can be restored by interaction of the displayed multimeric (poly)peptide complex with a corresponding partner coupled to an infectivity-mediating particle.

44. The phage vector fpep3\_1B-IR3seq with the sequence listed in Figure 4.


45. A phage vector derived from phage vector fpep3\_1B-IR3seq comprising essentially the phage origin or replication from fpep3\_1B-IR3seq, the gene II from fpep3\_1B-IR3seq, or a combination of said phage origin of replication and said gene II.

46. A phagemid vector derived from phage vector fpep3\_1B-IR3seq comprising essentially the phage origin or replication from fpep3\_1B-IR3seq, the gene II from fpep3\_1B-IR3seq, or a combination of said phage origin of replication and said gene II.


47. A helper phage vector derived from phage vector fpep3\_1B-IR3seq comprising essentially the phage origin or replication from fpep3\_1B-IR3seq, the gene II from fpep3\_1B-IR3seq, or a combination of said phage origin of replication and said gene II.


48. A vector according to anyone of claims 45 to 47, wherein said derivatives comprise the combined fd/f1 origin including the mutation G5737>A (2976 in fpep3\_1B-IR3seq), and/or the mutations G343>A (3989) in gII, and G601>T (4247) in gII/X.

49. The use according to any of the vectors of anyone of claims 44 to 48 in the generation of polyphage particles containing a combination of at least two different vectors.
50. The use according to claim 49, wherein said combination of different vectors comprises nucleic acid sequences encoding members of a multimeric (poly)peptide complex.
51. The use according to claim 50, wherein said combination of different vectors comprises nucleic acid sequences encoding interacting (poly)peptides/proteins.

**Figure 1: General description of the polyphage principle**

2/39

**Figure 1: General description of the polyphage principle (cont.)**

**Figure 2**

4/39

1 AACGCTACTA CCATTAGTAG AATTGATGCC ACCTTTCAAG CTCGCGCCCC  
 TTGCGATGAT GGTAATCATC TTAACTACGG TGAAAAGTC GAGCGCGGGG

51 AAATGAAAAT ATAGCTAAC AGGTTATTGA CCATTTGCGA AATGTATCTA  
 TTTACTTTA TATCGATTG TCCAATAACT GGTAAACGCT TTACATAGAT

101 ATGGTCAAAC TAAATCTACT CGTTCGCAGA ATTGGGAATC AACTGTTACA  
 TACCAGTTG ATTTAGATGA GCAAGCGTCT TAACCCTAG TTGACAATGT

151 TGGAATGAAA CTTCCAGACA CCGTACTTTA GTTGCATAATT TAAAACATGT  
 ACCTTACTTT GAAGGTCTGT GGCATGAAAT CAACGTATAA ATTTGTACA

201 TGAACCTACAG CACCAGATTG AGCAATTAAG CTCTAAGCCA TCCGCAAAAA  
 ACTTGATGTC GTGGTCTAAG TCGTTAATTG GAGATTGGT AGGCCTTTT

251 TGACCTCTTA TCAAAAGGAG CAATTAAAGG TACTGTCTAA TCCTGACCTG  
 ACTGGAGAAT AGTTTCCTC GTTAATTCC ATGACAGATT AGGACTGGAC

301 TTGGAATTG CTTCCGGTCT GGTCGCTTT GAGGCTCGAA TTGAAACGCG  
 AACCTTAAAC GAAGGCCAGA CCAAGCGAAA CTCCGAGCTT AACCTTGCAC

351 ATATTTGAAG TCTTCGGGC TTCCTCTTAA TCTTTTGAT GCAATTGCT  
 TATAAACTTC AGAAAGCCCG AAGGAGAATT AGAAAAACTA CGTTAAGCGA

401 TTGCTTCTGA CTATAATAGA CAGGGTAAAG ACCTGATTT TGATTTATGG  
 AACGAAGACT GATATTATCT GTCCCATTC TGACTAAAA ACTAAATACC

451 TCATTCTCGT TTTCTGAAC GTTTAAAGCA TTTGAGGGGG ATTCAATGAA  
 AGTAAGAGCA AAAGACTTGA CAAATTCTCGT AAACCTCCCC TAAGTTACTT

501 TATTTATGAC GATTCCGCAG TATTGGACGC TATCCAGTCT AAACATTAA  
 ATAAATACTG CTAAGCGTC ATAACCTGCG ATAGGTAGA TTTGTAAAAT

551 CAATTACCCC CTCTGGAAA ACTTCCTTTG CAAAAGCTC TCGCTATTAA  
 GTTAATGGGG GAGACCGTTT TGAAGGAAAC GTTTCCGAG AGCGATAAAA

601 GGTTTCTATC GTCGTCTGGT TAATGAGGGT TATGATAGTG TTGCTCTTAC  
 CCAAAGATAG CAGCAGACCA ATTACTCCC ATACTATCAC AACGAGAATG

651 CATGCCTCGT AATTCTTTT GGCGTTATGT ATCTGCATTA GTTGAGTGTG  
 GTACGGAGCA TTAAGGAAA CCGCAATACA TAGACGTAAT CAACTCACAC

701 GTATTCTAA ATCTCAATTG ATGAATCTT CCACCTGTAA TAATGTTGTT  
 CATAAGGATT TAGAGTTAAC TACTTAGAAA GGTGGACATT ATTACAACAA

751 CCGTTAGTTC GTTTTATTAA CGTAGATTT TCCTCCCAAC GTCCTGACTG  
 GGCAATCAAG CAAAATAATT GCATCTAAA AGGAGGGTTG CAGGACTGAC

801 GTATAATGAG CCAGTTCTTA AAATCGCATA AGGTAATTCA AAATGATTAA  
 CATATTACTC GGTCAAGAAT TTTAGCGTAT TCCATTAAGT TTTACTAATT

5/39

851 AGTTGAAATT AAACCGTCTC AAGCGCAATT TACTACCCGT TCTGGTGTAA  
TCAACTTAA TTTGGCAGAG TTCGCGTTAA ATGATGGCA AGACCACAAA

901 CTCGTCAGGG CAAGCCTTAT TCACTGAATG AGCAGCTTG TTACGTTGAT  
GAGCAGTCCC GTTCGGAATA AGTGAATTAC TCGTCGAAAC AATGCAACTA

951 TTGGGTAAATG AATATCCGGT GCTTGTCAAG ATTACTCTCG ACGAAGGTCA  
AACCCATTAC TTATAGGCCA CGAACAGTTC TAATGAGAGC TGCTTCCAGT

1001 GCCAGCGTAT GCGCCTGGTC TGTACACCGT GCATCTGTCC TCGTTCAAAG  
CGGTCGCATA CGCGGACCAAG ACATGTGGCA CGTAGACAGG AGCAAGTTTC

1051 TTGGTCAGTT CGGTTCTCTT ATGATTGACC GTCTGCGCCT CGTTCCGGCT  
AACCAAGTCAA GCCAAGAGAA TACTAACTGG CAGACGCGGA GCAAGGCCGA

1101 AAGTAACATG GAGCAGGTGG CGGATTCGA CACAATTAT CAGGCATGA  
TTCATTGTAC CTCGTCCAGC GCCTAAAGCT GTGTTAAATA GTCCGCTACT

1151 TACAAATCTC CGTTGTACTT TGTTTCGCGC TTGGTATAAT CGCTGGGGGT  
ATGTTTAGAG GCAACATGAA ACAAAAGCGC AACCATAATTA GCGACCCCCA

1201 CAAAGATGAG TGTTTAGTG TATTCTTCG CCTCTTCGT TTTAGGTTGG  
GTTTCTACTC ACAAAATCAC ATAAGAAAGC GGAGAAAGCA AAATCCAACC

1251 TGCCTTCGTA GTGGCATTAC GTATTTACC CGTTTAATGG AAACCTCCTC  
ACGGAAGCAT CACCGTAATG CATAAAATGG GCAAATTACC TTTGAAGGAG

1301 ATGCGTAAGT CTTTAGTCCT CAAAGCCTCC GTAGCCGTTG CTACCCCTCGT  
TACGCATTCA GAAATCAGGA GTTTCGGAGG CATCGGCAAC GATGGGAGCA

1351 TCCGATGCTG TCTTCGCTG CTGAGGGTGA CGATCCCGCA AAAGCGGCCT  
AGGCTACGAC AGAAAGCGAC GACTCCACT GCTAGGGCGT TTTCGCCCGGA

1401 TTGACTCCCT GCAAGCCTCA GCGACCGAAT ATATCGGTTA TGCCTGGGCG  
AACTGAGGGGA CGTCGGAGT CGCTGGCTTA TATAGCCAAT ACGCACCCGC

1451 ATGGTTGTTG TCATTGTCGG CGCAACTATC GGTATCAAGC TGTTAAGAA  
TACCAACAAC AGTAACAGCC GCGTTGATAG CCATAGTTCG ACAAATTCTT

1501 ATTACACCTCG AAAGCAAGCT GATAAAGGAG GTTTCTCGAT CGAGACGTTN  
TAAGTGGAGC TTTCGTTCGA CTATTCCTC CAAAGAGCTA GCTCTGCAAN

1551 NNNNGAGGTTCA AACTTTCAC CATAATGAAA TAAGATCACT ACCGGGCGTA  
NNNCTCCAAG GTTGAAAGTG GTATTACTTT ATTCTAGTGA TGGCCCGCAT

1601 TTTTTGAGT TATCGAGATT TTCAGGAGCT AAGGAAGCTA AAATGGAGAA  
AAAAAAACTCA ATAGCTCTAA AAGTCCTCGA TTCCCTCGAT TTTACCTCTT

1651 AAAAATCACT GGATATACCA CCGTTGATAT ATCCCAATGG CATCGTAAAG  
TTTTTAGTGA CCTATATGGT GGCAACTATA TAGGGTTACC GTAGCATTTC

6/39

1701 AACATTTGA GGCATTCAG TCAGTTGCTC AATGTACCTA TAACCAGACC  
TTGTAAAAGT CCGTAAAGTC AGTCAACGAG TTACATGGAT ATTGGTCTGG

1751 GTTCAGCTGG ATATTACGGC CTTTTAAAG ACCGTAAGA AAAATAAGCA  
CAAGTCGACC TATAATGCCG GAAAAATTTC TGGCATTCT TTTTATTCTG

1801 CAAGTTTAT CCGGCCTTA TTCACATTCT TGCCCGCCTG ATGAATGCTC  
GTTCAAAATA GGCGGAAAT AAGTGTAAAGA ACGGGCGGAC TACTTACGAG

1851 ATCCGGAGTT CCGTATGGCA ATGAAAGACG GTGAGCTGGT GATATGGGAT  
TAGGCCTCAA GGCATACCGT TACTTCTGC CACTCGACCA CTATACCCCTA

1901 AGTGTTCACC CTTGTTACAC CGTTTCCAT GAGCAAACGT AAACGTTTC  
TCACAAGTGG GAACAATGTG GCAAAAGGTAA CTCGTTGAC TTTGCAAAAG

1951 ATCGCTCTGG AGTGAATACC ACGACGATT CCAGCAGTTT CTACACATAT  
TAGCGAGACC TCACTTATGG TGCTGCTAA GGCGTCAAA GATGTGTATA

2001 ATTGCGAAGA TGTGGCGTGT TACGGTGAAA ACCTGGCCTA TTTCCCTAAA  
TAAGCGTTCT ACACCGCACA ATGCCACTT TGGACCGGAT AAAGGGATTT

2051 GGGTTTATTG AGAATATGTT TTTCGTCTCA GCCAATCCCT GGGTGAGTTT  
CCCAAATAAC TCTTATACAA AAAGCAGAGT CGGTTAGGGA CCCACTCAAA

2101 CACCAAGTTT GATTAAACG TGGCCAATAT GGACAACTTC TTGCCCCCG  
GTGGTCAAAA CTAAATTGC ACCGGTTATA CCTGTTGAAG AAGCGGGGGC

## NcoI

~~~~~

2151 TTTTCACCAT GGGCAAATAT TATACGCAAG GCGACAAGGT GCTGATGCCG  
AAAAGTGGTA CCCGTTATA ATATGCGTTC CGCTGTTCCA CGACTACGGC

2201 CTGGCGATTC AGGTTCATCA TGCCGTCTGT GATGGCTTCC ATGTCGGCAG  
GACCGCTAAG TCCAAGTAGT ACGGCAGACA CTACCGAAGG TACAGCCGTC

2251 AATGCTTAAT GAATTACAAAC AGTACTGCGA TGAGTGGCAG GGCGGGCGT  
TTACGAATTA CTTAATGTTG TCATGACGCT ACTCACCCTC CCGCCCCGCA

2301 AATTTTTTA AGGCAGTTAT TGGTGCCTT AAACGCCTGG TGCTACGCCT  
TTAAAAAAAT TCCGTCATA ACCACGGAA TTTGCGGACC ACGATGCGGA

2351 GAATAAGTGA TAATAAGCGG ATGAATGGCA GAAATTGAA AGCAAATTG  
CTTATTCACT ATTATCGCC TACTTACCGT CTTTAAGCTT TCGTTAAGC

2401 ACCCGGTCGT CGGTTCAAGGG CAGGGTCGTT AAATAGCCGC TTATGTCTAT  
TGGGCCAGCA GCCAAGTCCC GTCCCAGCAA TTTATCGGCG AATACAGATA

2451 TGCTGGTTA CCGGTTTATT GACTACCGGA AGCAGTGTGA CCGTGTGCTT  
ACGACCAAAT GGCAAATAA CTGATGGCCT TCGTCACACT GGCACACGAA

2501 CTCAAATGCC TGAGGCCAGT TTGCTCAGGC TCTCCCCGTG GAGGTAATAA  
GAGTTTACGG ACTCCGGTCA AACGAGTCCG AGAGGGGCAC CTCCATTATT

7/39

2551 TTGCTCGACC GATAAAAGCG GCTTCCTGAC AGGAGGCCGT TTTGTTTGC  
 AACGAGCTGG CTATTTCGC CGAAGGACTG TCCTCCGGCA AAACAAAACG  
 2601 AGCCCACCTC AACGCAATT AATGTGAGTTA GCTCACTCAT TAGGCACCCC  
 TCGGGTGGAG TTGCGTTAAT TACACTCAAT CGAGTGAGTA ATCCGTGGGG  
 2651 AGGCTTTACA CTTTATGCTT CCGGCTCGTA TGTTGTGTGG AATTGTGAGC  
 TCCGAAATGT GAAATACGAA GGCGGAGCAT ACAACACACC TTAACACTCG  
 2701 GGATAACAAT TTCACACAGG AAACAGCTAT GACCATGATT ACGAATTCT  
 CCTATTGTTA AAGTGTGTCC TTTGTCGATA CTGGTACTAA TGCTTAAAGA  
 2751 AGATAACGAG GGCAAATCAT GAAAAAGACA GCTATCGCGA TTGCAGTGGC  
 TCTATTGCTC CCGTTTAGTA CTTTTCTGT CGATAGCGCT AACGTCACCG  
 2801 ACTGGCTGGT TTCGCTACCG TAGCGCAGGC CGACTACAAA GATATCGTTA  
 TGACCGACCA AAGCGATGGC ATCGCGTCCG GCTGATGTTT CTATAGCAAT  
 2851 TGACCCAGTC ACCGTCTCC CTGACCGTTA CCGCTGGTGA AAAAGTTACC  
 ACTGGGTCAAG TGGCAGGAGG GACTGGCAAT GGCGACCACT TTTTCAATGG  
 2901 ATGTCCTGCA CCTCCTCCCA GTCCCTGTT AACTCCGGTA AACAGAAAAA  
 TACAGGACGT GGAGGAGGGT CAGGGACAAG TTGAGGCCAT TTGCTTTTT  
 2951 CTACCTGACC TGGTATCAGC AGAAACCGGG TCAGCCACCG AAAGTTCTGA  
 GATGGACTGG ACCATAGTCG TCTTGGCCC AGTCGGTGGC TTTCAAGACT  
 3001 TCTACTGGGC TTCCACCCGT GAATCCGGTG TTCCAGACCG TTTCACCGGT  
 AGATGACCCG AAGGTGGCA CTTAGGCCAC AAGGTCTGGC AAAGTGGCCA  
 3051 TCCGGTTCCG GCACCGACTT CACCCGTGACC ATCTCCTCCG TTCAGGCTGA  
 AGGCCAAGGC CGTGGCTGAA GTGGGACTGG TAGAGGAGGC AAGTCCGACT  
 3101 AGACCTGGCT GTTTACTACT GCCAGAACGA CTACTCCAAC CCACTGACCT  
 TCTGGACCGA CAAATGATGA CGGTCTTGCT GATGAGGTTG GGTGACTGGA  
 3151 TCGGTGGTGG CACCAAACGT GAACTTAAGC GCGCTGGTGG TGGAGGGTCT  
 AGCCACCACC GTGGTTGAC CTTGAATTGCG CGCGACCACC ACCTCCCAGA

## BamHI

-----

3201 GGAGGAGGTG GGAGTGGGGG AGGTGGATCC GGCGGGGGAG GTTCAGGGGG  
 CCTCCTCCAC CCTCACCCCC TCCACCTAGG CCGCCCCCTC CAAGTCCCCC  
 3251 TGGCGGTAGT GGAGGGGGCG GTTCAGAAAGT TCAACTAGTT GAATCCGGTG  
 ACCGCCATCA CCTCCCCCGC CAAGTCTTCA AGTTGATCAA CTTAGGCCAC  
 3301 GTGACCTGGT TAAACCGGGT GGTTCCCTGA AACTGTCTG CGCTGTTCC  
 CACTGGACCA ATTTGGCCCA CCAAGGGACT TTGACAGGAC GCGACGAAGG

8/39

3351 GGTTTCTCCT TCTCCTCCTA CGGTATGTCC TGGGTTCGTC AGACCCCGGA  
CCAAAGAGGA AGAGGAGGAT GCCATACAGG ACCCAAGCAG TCTGGGGCCT

3401 CAAACGTCTG GAATGGGTTG CTACCATCTC CAACGGTGGT GGTTACACCT  
GTTTGCAGAC CTTACCCAAC GATGGTAGAG GTTGCCACCA CCAATGTGGA

3451 ACTACCCGGA CTCCGTTAAA GGTCGTTCA CCATCTCCCG TGACAAACGCT  
TGATGGGCCT GAGGCAATT CCAGCAAAGT GGTAGAGGGC ACTGTTGCGA

PstI

3501 -----  
AAAAACACCC TGTACCTGCA GATGTCTCC CTGAAATCCG AAGACTCAGC  
TTTTTGTGGG ACATGGACGT CTACAGGAGG GACTTTAGGC TTCTGAGTCG

3551 -----  
TATGTACTAC TGCGCTCGTC GTGAACGTTA CGACGAAAAC GGTTTCGCTT  
ATACATGATG ACGCGAGCAG CACTTGCAAT GCTGCTTTG CCAAAGCGAA

EcoRI

3601 -----  
ACTGGGGTCA GGGTACCCCTG GTTACCGTTT CAGCTTCCGG AGAATTGAG  
TGACCCCACT CCCATGGAC CAATGGCAA GTCGAAGGCC TCTTAAGCTC

AvaI

3651 -----  
GCCTCGGGGG CCGAGGGCGG CGGTTCTGGT TCCGGTGATT TTGATTATGA  
CGGAGCCCCC GGCTCCCGCC GCCAAGACCA AGGCCACTAA AACTAATACT

3701 -----  
AAAAATGGCA AACGCTAATA AGGGGGCTAT GACCGAAAAT GCCGATGAAA  
TTTTTACCGT TTGCGATTAT TCCCCCGATA CTGGCTTTA CGGCTACTTT

3751 -----  
ACGCGCTACA GTCTGACGCT AAAGGCAAAC TTGATTCTGT CGCTACTGAT  
TGCGCGATGT CAGACTGCGA TTTCCGTTG AACTAAGACA GCGATGACTA

ClaI

3801 -----  
TACGGTCTG CTATCGATGG TTTCATTGGT GACGTTCCG GCCTTGCTAA  
ATGCCACGAC GATAGCTACC AAAGTAACCA CTGCAAAGGC CGGAACGATT

3851 -----  
TGGTAATGGT GCTACTGGTG ATTTGCTGG CTCTAATTCC CAAATGGCTC  
ACCATTACCA CGATGACCAC TAAAACGACC GAGATTAAGG GTTTACCGAG

3901 -----  
AAGTCGGTGA CGGTGATAAT TCACCTTAA TGAATAATT CCGTCAATAT  
TTCAGCCACT GCCACTATTA AGTGGAAATT ACTTATTAAA GGCAGTTATA

3951 -----  
TTACCTTCCC TCCCTCAATC GGTTGAATGT CGCCCTTTG TCTTGGCGC  
AATGGAAGGG AGGGAGTTAG CCAACTTACA GCGGGAAAAC AGAAACCGCG

4001 -----  
TGGTAAACCA TATGAATTCTT CTATTGATTG TGACAAAATA AACTTATTCC  
ACCATTGGT ATACTTAAAA GATAACTAAC ACTGTTTAT TTGAATAAGG

4051 -----  
GTGGTGTCTT TGCGTTCTT TTATATGTTG CCACCTTTAT GTATGTATTT  
CACCACAGAA ACGCAAAGAA AATATACAAC GGTGGAAATA CATAACATAAA

9/39

HindIII

4101 TCTACGTTG CTAACATACT GCGTAATAAG GAGTCTTGAT AAGCTTCGAG  
AGATGCAAAC GATTGTATGA CGCATTATTC CTCAGAACTA TTCGAAGCTC

4151 AAATTCAACCT CGAAAGCAAG CTGATAAACCC GATACAATTA AAGGCTCCTT  
TTTAAGTGG A GCTTTCGTT GACTATTGG CTATGTTAAT TTCCGAGGAA

EcoRI

4201 TTGGAGCCTT TTTTTTGGA GAATTCAATC ATGCCAGTTC TTTGGGTAT  
AACCTCGGAA AAAAAAACCT CTTAAGTTAG TACGGTCAAG AAAACCCATA

4251 TCCGTTATTA TTGCGTTCC TCGGTTCCCT TCTGGTAAC TTGTTCGGCT  
AGGCAATAAT AACGCAAAGG AGCCAAAGGA AGACCATTGA ACAAGCCGA

4301 ATCTGCTTAC TTTCCTTAAA AAGGGCTTCG GTAAGATAAGC TATTGCTATT  
TAGACGAATG AAAGGAATT TTCCCGAAGC CATTCTATCG ATAACGATAA

4351 TCATTGTTTC TTGCTCTTAT TATTGGGCTT AACTCAATTC TTGTTGGTTA  
AGTAACAAAG AACGAGAATA ATAACCGAA TTGAGTTAAG AACACCCAAT

4401 TCTCTCTGAT ATTAGCGCAC AATTACCCCTC TGATTTGTT CAGGGCGTTC  
AGAGAGACTA TAATCGCGTG TTAATGGGAG ACTAAAACAA GTCCCGAAG

4451 AGTTAATTCT CCCGTCTAAT GCGCTCCCT GTTTTATGT TATTCTCTCT  
TCAATTAAGA GGGCAGATTA CGCGAAGGGA CAAAAATACA ATAAGAGAGA

4501 GTAAAGGCTG CTATTTCAT TTTGACGTT AAACAAAAAA TCGTTCTTA  
CATTCCGAC GATAAAAGTA AAAACTGCAA TTTGTTTTT AGCAAAGAAT

4551 TTTGGATTGG GATAAAATAAA TATGGCTGTT TATTTGTAA CTGGCAAATT  
AAACCTAACCT CTATTTATTT ATACCGACAA ATAAAACATT GACCGTTAA

4601 AGGCTCTGGA AAGACGCTCG TTAGCGTTGG TAAGATTCAAG GATAAAATTG  
TCCGAGACCT TTCTGCGAGC AATCGCAACC ATTCTAAGTC CTATTTAAC

4651 TAGCTGGGTG CAAAATAGCA ACTAATCTTG ATTTAAGGCT TCAAAACCTC  
ATCGACCCAC GTTTATCGT TGATTAGAAC TAAATTCCGA AGTTTGAG

4701 CCGCAAGTCG GGAGGTTCGC TAAAACGCCT CGCGTTCTTA GAATACCGGA  
GGCGTTCAAGCG CCTCCAAGCG ATTTTGCAGA GCGCAAGAAT CTTATGGCCT

4751 TAAGCCTTCT ATTTCTGATT TGCTTGCTAT TGGTCGTGGT AATGATTCCCT  
ATTCCGAAGA TAAAGACTAA ACGAACGATA ACCAGCACCA TTACTAAGGA

4801 ACGACGAAAA TAAAAACGGT TTGCTTGTTC TTGATGAATG CGGTACTTGG  
TGCTGCTTTT ATTTTGCCA AACGAACAAG AACTACTTAC GCCATGAACC

4851 TTTAATACCC GTTCATGGAA TGACAAGGAA AGACAGCCGA TTATTGATTG  
AAATTATGGG CAAGTACCTT ACTGTTCCCT TCTGTCGGCT AATAACTAAC

10/39

4901 GTTTCTTCAT GCTCGTAAAT TGGGATGGGA TATTATTTT CTTGTTCAGG  
 CAAAGAAGTA CGAGCATTAA ACCCTACCCCT ATAATAAAAAA GAACAAGTCC  
  
 4951 ATTTATCTAT TGGTGTAA CAGGCGCGTT CTGCATTAGC TGAACACGTT  
 TAAATAGATA ACAACTATT GTCCGCGCAA GACGTAATCG ACTTGTGCAA  
  
 5001 GTTTATTGTC GCCGTCTGGA CAGAATTACT TTACCCCTTG TCGGCACCTT  
 CAAATAACAG CGGCAGACCT GTCTTAATGA AATGGGAAAC AGCCGTGAAA  
  
 5051 ATATTCTCTT GTTACTGGCT CAAAAATGCC TCTGCCTAAA TTACATGTTG  
 TATAAGAGAA CAATGACCGA GTTTTACGG AGACGGATT AATGTACAAC  
  
 5101 GTGTTGTTAA ATATGGTGT TCTCAATTAA GCCCTACTGT TGAGCGTTGG  
 CACAACAATT TATACCACTA AGAGTTAATT CGGGATGACA ACTCGCAAC  
  
 5151 CTTTATACTG GTAAGAATT ATATAACGCA TATGACACTA AACAGGCTTT  
 GAAATATGAC CATTCTAAA TATATTGCGT ATACTGTGAT TTGTCGAAA  
  
 5201 TTCCAGTAAT TATGATTCAAG GTGTTTATTCA ATATTTAACCC CTTTATTAT  
 AAGGTCATTA ATACTAAGTC CACAAATAAG TATAAATTGG GGAATAAAATA  
  
 5251 CACACGGTCG GTATTTCAAA CCATTAATT TAGGTCAGAA GATGAAATTAA  
 GTGTGCCAGC CATAAAAGTTT GGTAATTAA ATCCAGTCTT CTACTTTAAT  
  
 5301 ACTAAAATAT ATTGAAAAA GTTTCTCGC GTTCTTGTC TTGCGATAGG  
 TGATTTATA TAAACTTTT CAAAAGAGCG CAAGAAACAG AACGCTATCC  
  
 5351 ATTTGCATCA GCATTTACAT ATAGTTATAT AACCCAACCT AAGCCGGAGG  
 TAAACGTAGT CGTAAATGTA TATCAATATA TTGGGTTGGA TTGGCCCTCC  
  
 5401 TTAAAAAGGT AGTCTCTCAG ACCTATGATT TTGATAAATT CACTATTGAC  
 AATTTTCCA TCAGAGAGTC TGGATACTAA AACTATTTAA GTGATAACTG  
  
 5451 TCTTCTCAGC GTCTTAATCT AAGCTATCGC TATGTTTCA AGGATTCTAA  
 AGAAGAGTCG CAGAATTAGA TTGATAGCG ATACAAAAGT TCCTAAGATT  
  
 5501 GGGAAAATTA ATTAATAGCG ACGATTACA GAAGCAAGGT TATTCCATCA  
 CCCTTTAAT TAATTATCGC TGCTAAATGT CTTCGTTCCA ATAAGGTAGT  
  
 5551 CATATATTGA TTTATGTACT GTTTCAATTAA AAAAAGGTAA TTCAAATGAA  
 GTATATAACT AAATACATGA CAAAGTTAAT TTTTCCATT AAGTTTACTT  
  
 5601 ATTGTTAAAT GTAATTAAATT TTGTTTCTT GATGTTGTT TCATCATCTT  
 TAACAATTAA CATTAATTAA AACAAAAGAA CTACAAACAA AGTAGTAGAA  
  
 5651 CTTTGCTCA AGTAATTGAA ATGAATAATT CGCCTCTGCG CGATTCGTG  
 GAAAACGAGT TCATTAACCT TACTTATTAA GCGGAGACGC GCTAAAGCAC  
  
 5701 ACTTGGTATT CAAAGCAAAC AGGTGAATCT GTTATTGTCT CACCTGATGT  
 TGAACCATAA GTTTCGTTG TCCACTTAGA CAATAACAGA GTGGACTACA

11/39

5751 TAAAGGTACA GTGACTGTAT ATTCCCTCTGA CGTTAACGCCT GAAAATTTAC  
 ATTTCCATGT CACTGACATA TAAGGAGACT GCAATTGGA CTTTTAAATG  
 5801 GCAATTCTT TATCTCTGTT TTACGTGCTA ATAATTTGA TATGGTTGGC  
 CGTTAAAGAA ATAGAGACAA AATGCACGAT TATTAAAATC ATACCAACCG  
 5851 TCAATTCTT CCATAATTCA GAAATATAAC CCAAATAGTC AGGATTATAT  
 AGTTAAGGAA GGTATTAAGT CTTTATATTG GGTTTATCAG TCCTAATATA  
 5901 TGATGAATTG CCATCATCTG ATATTCAAGGA ATATGATGAT AATTCCGCTC  
 ACTACTAAC GGTAGTAGAC TATAAGTCCT TATACTACTA TTAAGGCGAG  
 5951 CTTCTGGTGG TTTCTTTGTT CCGCAAAATG ATAATGTTAC TCAAACATT  
 GAAGACCACC AAAGAAACAA GGCGTTTAC TATTACAATG AGTTTGTAAA  
 6001 AAAATTAATA ACGTTCGCGC AAAGGATTAA ATAAGGGTTG TAGAATTGTT  
 TTTTAATTAT TGCAAGCGCG TTTCTAAAT TATTCCCAAC ATCTTAACAA  
 6051 TGTTAAATCT AATACATCTA AATCCTCAAA TGTATTATCT GTTGATGGTT  
 ACAATTAGA TTATGTAGAT TTAGGAGTTT ACATAATAGA CAACTACCAA  
 6101 CTAACTTATT AGTAGTTAGC GCCCCTAAAG ATATTTAGA TAAACCTTCCG  
 GATTGAATAA TCATCAATCG CGGGGATTTC TATAAAATCT ATTGGAAGGC  
 6151 CAATTCTTT CTACTGTTGA TTTGCCAACT GACCAGATAT TGATTGAAGG  
 GTTAAAGAAA GATGACAACAA AACCGTTGA CTGGTCTATA ACTAACTTCC  
 6201 ATTAATTTC GAGGTTCAAG AAGGTGATGC TTTAGATTT TCCTTGCTG  
 TAATTAAAAG CTCCAAGTCG TTCCACTACG AAATCTAAA AGGAAACGAC  
 6251 CTGGCTCTCA GCGCGGCACT GTTGCTGGTG GTGTTAATAC TGACCGTCTA  
 GACCGAGAGT CGCGCCGTGA CAACGACCAC CACAATTATG ACTGGCAGAT  
 6301 ACCTCTGTT TATCTCTGC GGGTGGTTCG TTCGGTATTT TTAACGGCGA  
 TGGAGACAAA ATAGAAGACG CCCACCAAGC AAGCCATAAA AATTGCCGCT  
 6351 TGTTTAGGG CTATCAGTTC GCGCATTAAA GACTAATAGC CATTAAAAAA  
 ACAAAATCCC GATAGTCAAG CGCGTAATTCT GTGATTATCG GTAAGTTTT  
 6401 TATTGTCTGT GCCTCGTATT CTTACGCTTT CAGGTCAAGAA GGTTCTATT  
 ATAACAGACA CGGAGCATAA GAATGCGAAA GTCCAGTCTT CCCAAGATAA  
 6451 TCTGTTGGCC AGAATGTCCC TTTTATTACT GGTCGTGTAA CTGGTGAATC  
 AGACAACCGG TCTTACAGGG AAAATAATGA CCAGCACATT GACCACTTAG  
 6501 TGCCAATGTA AATAATCCAT TTCAAGACGGT TGAGCGTCAA AATGTTGGTA  
 ACGGTTACAT TTATTAGGTA AAGTCTGCCA ACTCGCAGTT TTACAACCAT  
 6551 TTTCTATGAG TGTTTTCCC GTTGCAATGG CTGGCGGTAA TATTGTTTA  
 AAAGATACTC ACAAAAAGGG CAACGTTACC GACCGCCATT ATAACAAAAT

12/39

6601 GATATAACCA GTAAGGCCGA TAGTTGAGT TCTTCTACTC AGGCAAGTGA  
 CTATATTGGT CATTCCGGCT ATCAAACCTCA AGAAGATGAG TCCGTTCACT  
  
 6651 TGTTATTACT AATCAAAGAA GTATTGCGAC AACGGTTAAT TTGCGTGATG  
 ACAATAATGA TTAGTTCTT CATAACGCTG TTGCCAATTA AACGCACTAC  
  
 6701 GTCAGACTCT TTTGCTCGGT GGCCTCACTG ATTACAAAAA CACTTCTCAA  
 CAGTCTGAGA AAACGAGCCA CCGGAGTGAC TAATGTTTT GTGAAGAGTT  
  
 6751 GATTCTGGTG TGCCGTTCCCT GTCTAAAATC CCTTTAATCG GCCTCCTGTT  
 CTAAGACAC ACGGCAAGGA CAGATTTAG GGAAATTAGC CGGAGGACAA  
  
 6801 TAGCTCCCGT TCTGATTCTA ACGAGGAAAG CACGTTGTAC GTGCTCGTCA  
 ATCGAGGGCA AGACTAAGAT TGCTCCTTTC GTGCAACATG CACGAGCAGT  
  
 6851 AAGCAACCAT AGTACGCGCC CTGTAGCGGC GCATTAAGCG CGGCGGGTGT  
 TTCGTTGGTA TCATGCGCG GACATCGCCG CGTAATTCGC GCCGCCACAA  
  
 6901 GGTGGTTACG CGCAGCGTGA CCGCTACACT TGCCAGCGCC CTAGCGCCCG  
 CCACCAATGC GCGTCGCACT GGCGATGTGA ACGGTCGCGG GATCGCGGGC  
  
 6951 CTCCCTTCGC TTTCTTCCCT TCCTTTCTCG CCACGTTCTC CGGCTTTCCC  
 GAGGAAAGCG AAAGAAGGGA AGGAAAGAGC GGTGCAAGAG GCCGAAAGGG

## BamHI

~~~~~

7001 CGTCAAGCTC TAAATCGGGG GATCCCTTA GGGTTCCGAT TTAGTGCTTT  
 GCAGTTCGAG ATTTAGCCCC CTAGGGAAAT CCCAAGGCTA AATCACGAAA  
  
 7051 ACGGCACCTC GACCTCCAAA AACTTGATTT GGGTGATGGT TCACGTAGTG  
 TGCCGTGGAG CTGGAGGTTT TTGAACTAAA CCCACTACCA AGTGCATCAC  
  
 7101 GCCCATCGCC CTGATAGACG GTTTTCGCC CTTTGACGTT GGAGTCCACG  
 CCGTAGCGG GACTATCTGC CAAAAAGCGG GAAACTGCAA CCTCAGGTGC  
  
 7151 TTCTTTAATA GTGGACTCTT GTTCCAAACT GGAACAAACAC TCACAACTAA  
 AAGAAATTAT CACCTGAGAA CAAGGTTGA CCTTGTGTTG AGTGTGATT  
  
 7201 CTCGGCCTAT TCTTTGATT TATAAGGATT TTTGTCATTT TCTGCTTACT  
 GAGCCGGATA AGAAAACCTAA ATATTCTAA AAACAGTAAA AGACGAATGA  
  
 7251 GTTAAAAAAA TAAGCTGATT TAACAAATAT TTAACCGAA ATTTAACAAA  
 CCAATTGTTT ATTGCACTAA ATTGTTATA AATTGCGCTT TAAATTGTTT  
  
 7301 ACATTAACGT TTACAATTAA AATATTGCT TATACAATCA TCCTGTTTT  
 TGTAATTGCA AATGTTAAAT TTATAAACGA ATATGTTAGT AGGACAAAAA  
  
 7351 GGGGCTTTTC TGATTATCAA CGGGGGTACA TATGATTGAC ATGCTAGTTT  
 CCCCAGAAAG ACTAATAGTT GGCCCCATGT ATACTAACTG TACGATCAAA

13/39

Clal

7401 TACGATTACC GTTCATCGAT TCTCTTGT TT GCTCCAGACT TTCAGGTAAT  
ATGCTAATGG CAAGTAGCTA AGAGAACAAA CGAGGTCTGA AAGTCCATTA

7451 GACCTGATAG CCTTTGTAGA CCTCTCAAAA ATAGCTACCC TCTCCGGCAT  
CTGGACTATC GGAAACATCT GGAGAGTTT TATCGATGGG AGAGGCCGTA

7501 GAATTTATCA GCTAGAACGG TTGAATATCA TATTGACGGT GATTTGACTG  
CTTAAATAGT CGATCTGCC AACTTATAGT ATAACTGCCA CTAAACTGAC


7551 TCTCCGGCCT TTCTCACCCG TTTGAATCTT TGCCTACTCA TTACTCCGGC  
AGAGGCCGGA AAGAGTGGGC AAACTTAGAA ACGGATGAGT AATGAGGCCG

7601 ATTGCATTTA AAATATATGA GGGTTCTAAA AATTTTATC CCTGCCTTGA  
TAACGTAAAT TTTATATACT CCCAAGATTT TTAAAAATAG GGACGCAACT

7651 AATTAAGGCT TCACCAGCAA AAGTATTACA GGGTCATAAT GTTTTGGTA  
TTAATTCCGA AGTGGTCGTT TTCATAATGT CCCAGTATTA CAAAAACCAT

7701 CAACCGATTT AGCTTTATGC TCTGAGGCTT TATTGCTTAA TTTTGCTAAC  
GTTGGCTAAA TCGAAATACG AGACTCCGAA ATAACGAATT AAAACGATTG

7751 TCTCTGCCTT GCTTGTACGA TTTATTGGAT GTT  
AGAGACGGAA CGAACATGCT AAATAACCTA CAA

**Figure 3**

15/39

1 AACGCTACTA CCATTAGTAG AATTGATGCC ACCTTTCA G CTCGCGCCCC  
 TTGCGATGAT GGTAAATCATC TTAAC TACGG TGGAAAAGTC GAGCGCGGGG  
  
 51 AAATGAAAAT ATAGCTAAC AGGTTATTGA CCATTTGCGA AATGTATCTA  
 TTTACTTTA TATCGATTTG TCCAATAACT GGTAAACGCT TTACATAGAT  
  
 101 ATGGTCAAAC TAAATCTACT CGTTCCGAGA ATTGGGAATC AACTGTTACA  
 TACCAGTTG ATTTAGATGA GCAAGCGTCT TAACCCTTAG TTGACAATGT  
  
 151 TGGAATGAAA CTTCCAGACA CCGTACTTTA GTTGCATATT TAAAACATGT  
 ACCTTACTTT GAAGGTCTGT GGCATGAAAT CAACGTATAA ATTTGTACA  
  
 201 TGAAC TACAG CACCAGATT C AGCAATTAAG CTCTAAGCCA TCCGCAAAAA  
 ACTTGATGTC GTGGTCTAAG TCGTTAATTG GAGATT CGGT AGGCGTTTT  
  
 251 TGACCTCTTA TCAAAAGGAG CAATTAAAGG TACTGTCTAA TCCTGACCTG  
 ACTGGAGAAT AGTTTCCTC GTTAATTCC ATGACAGATT AGGACTGGAC  
  
 301 TTGGAATTG CTTCCGGTCT GGTTCGCTTT GAGGCTCGAA TTGAAACGCG  
 AACCTTAAAC GAAGGCCAGA CCAAGCGAAA CTCCGAGCTT AACTTGCGC  
  
 351 ATATTTGAAG TCTTCGGGC TTCTCTTAA TCTTTTGAT GCAATTGCT  
 TATAAACTTC AGAAAGCCCG AAGGAGAATT AGAAAAACTA CGTTAAGCGA  
  
 401 TTGCTTCTGA CTATAATAGA CAGGGTAAAG ACCTGATTT TGATTTATGG  
 AACGAAGACT GATATTATCT GTCCCATTTC TGGACTAAAA ACTAAATACC  
  
 451 TCATTCTCGT TTTCTGA ACT GTTTAAAGCA TTTGAGGGGG ATTCAATGAA  
 AGTAAGAGCA AAAGACTTGA CAAATTCTCGT AAACCTCCCC TAAGTTACTT  
  
 501 TATTTATGAC GATTCCGCAG TATTGGACGC TATCCAGTCT AAACATTTA  
 ATAAATACTG CTAAGGCCTC ATAACCTGCG ATAGGTAGA TTTGTAAAAT  
  
 551 CAATTACCCC CTCTGGCAAA ACTTCCTTTG CAAAAGCCTC TCGCTATTTT  
 GTTAATGGGG GAGACCGTTT TGAAGGAAAC GTTTCCGAG AGCGATAAAA  
  
 601 GGTTTCTATC GTCGCTGGT TAATGAGGGT TATGATAGTG TTGCTCTTAC  
 CCAAAGATAG CAGCAGACCA ATTACTCCCA ATACTATCAC AACGAGAATG  
  
 651 CATGCCTCGT AATTCTTTT GGC GTTATGT ATCTGCATTA GTTGAGTGTG  
 GTACGGAGCA TTAAGGAAA CCGCAATACA TAGACGTAAT CAACTCACAC  
  
 701 GTATTCTAA ATCTCAATTG ATGAATCTTT CCACCTGTAA TAATGTTGTT  
 CATAAGGATT TAGAGTTAAC TACTTAGAAA GGTGGACATT ATTACAACAA  
  
 751 CCGTTAGTTC GTTTTATTAA CGTAGATTT TCCTCCAAAC GTCCTGACTG  
 GCGAATCAAG CAAAATAATT GCATCTAAA AGGAGGGTTG CAGGACTGAC  
  
 801 GTATAATGAG CCAGTTCTTA AAATCGCATA AGGTAATTCA AAATGATTAA  
 CATATTACTC GGTCAAGAAT TTTAGCGTAT TCCATTAAGT TTTACTAATT

16/39

851 AGTTGAAATT AAACCGTCTC AAGCGCAATT TACTACCCGT TCTGGTGTAA  
TCAACTTAA TTTGGCAGAG TTGCGCTTAA ATGATGGGCA AGACCACAAA

901 CTCGTCAGGG CAAGCCTTAT TCACTGAATG AGCAGCTTG TTACGTTGAT  
GAGCAGTCCC GTTCGGAATA AGTGAATTAC TCGTCGAAAC AATGCAACTA

951 TTGGGTAAATG AATATCCGGT GCTTGTCAAG ATTACTCTCG ACGAAGGTCA  
AACCCATTAC TTATAGGCCA CGAACAGTTC TAATGAGAGC TGCTTCCAGT

1001 GCCAGCGTAT GCGCCTGGTC TGTACACCGT GCATCTGTCC TCGTTCAAAG  
CGGTCGCATA CGCGGACCAG ACATGTGGCA CGTAGACAGG AGCAAGTTTC

1051 TTGGTCAGTT CGGGTCTCTT ATGATTGACC GTCTGCGCCT CGTTCCGGCT  
AACCAAGTCAA GCCAAGAGAA TACTAACTGG CAGACGCGGA GCAAGGCCGA

1101 AAGTAACATG GAGCAGGTGCG CGGATTTCGA CACAATTAT CAGGCGATGA  
TTCATTGTAC CTCGTCCAGC GCCTAAAGCT GTGTTAAATA GTCCGCTACT

1151 TACAAATCTC CGTTGTACTT TGTTTCGCGC TTGGTATAAT CGCTGGGGT  
ATGTTTAGAG GCAACATGAA ACAAGCGCG AACCATATTA GCGACCCCCA

1201 CAAAGATGAG TGTTTTAGTG TATTCTTCG CCTCTTCGT TTTAGGTTGG  
GTTTCTACTC ACAAAATCAC ATAAGAAAGC GGAGAAAGCA AAATCCAACC

1251 TGCCTTCGTA GTGGCATTAC GTATTTTAC CGTTTAATGG AAACCTCCTC  
ACGGAAGCAT CACCGTAATG CATAAAATGG GCAAATTACC TTTGAAGGAG

1301 ATGCGTAAGT CTTTAGTCCT CAAAGCCTCC GTAGCCGTG CTACCCCTCGT  
TACGCATTCA GAAATCAGGA GTTTCGGAGG CATCGGCAAC GATGGGAGCA

1351 TCCGATGCTG TCTTCGCTG CTGAGGGTGA CGATCCCGCA AAAGCGGCCT  
AGGCTACGAC AGAAAGCGAC GACTCCCACT GCTAGGGCGT TTTCGCCGGA

1401 TTGACTCCCT GCAAGCCTCA GCGACCGAAT ATATCGGTTA TGCGTGGCG  
AACTGAGGGA CGTCGGAGT CGCTGGCTTA TATAGCCAAT ACGCACCCGC

1451 ATGGTTGTTG TCATTGTCGG CGCAACTATC GGTATCAAGC TGTTAAGAA  
TACCAACAAC AGTAACAGCC GCGTTGATAG CCATAGTTCG ACAAATTCTT

1501 ATTACACCTCG AAAGCAAGCT GATAAAGGAG GTTTCTCGAT CGAGACGTTN  
TAAGTGGAGC TTTCGTTCA CTATTCCTC CAAAGAGCTA GCTCTGCAAN

1551 NNNNGAGGTTTC CAACTTTCAC CATAATGAAA TAAGATCACT ACCGGCGTA  
NNNCTCCAAG GTTGAAGTG GTATTACTTT ATTCTAGTGA TGGCCCGCAT

1601 TTTTTGAGT TATCGAGATT TTCAGGAGCT AAGGAAGCTA AAATGGAGAA  
AAAAAAACTCA ATAGCTCTAA AAGTCCTCGA TTCCCTCGAT TTTACCTCTT

1651 AAAAATCACT GGATATACCA CCGTTGATAT ATCCCAATGG CATCGTAAAG  
TTTTTAGTGA CCTATATGGT GGCAACTATA TAGGGTTACC GTAGCATTTC

17/39

1701 AACATTTGA GGCATTCAG TCAGTTGCTC AATGTACCTA TAACCAGACC  
 TTGTAAAAGT CCGTAAAGTC AGTCAACGAG TTACATGGAT ATTGGTCTGG  
  
 1751 GTTCAGCTGG ATATTACGGC CTTTTAAAG ACCGTAAGA AAAATAAGCA  
 CAAGTCGACC TATAATGCCG GAAAAATTTC TGGCATTCT TTTTATTCTG  
  
 1801 CAAGTTTAT CCGGCCTTTA TTCACATTCT TGCCCGCTG ATGAATGCTC  
 GTTCAAAATA GGCGGAAAT AAGTGTAAAGA ACGGGCGGAC TACTTACGAG  
  
 1851 ATCCGGAGTT CCGTATGGCA ATGAAAGACG GTGAGCTGGT GATATGGGAT  
 TAGGCCTCAA GGCATACCGT TACTTCTGC CACTCGACCA CTATACCCCTA  
  
 1901 AGTGTTCACC CTTGTTACAC CGTTTCCAT GAGCAAACGT AAACGTTTTC  
 TCACAAGTGG GAACAATGTG GCAAAAGGTA CTCGTTGAC TTTGCAAAAG  
  
 1951 ATCGCTCTGG AGTGAATACC ACGACGATTT CCGGCAGTTT CTACACATAT  
 TAGCGAGACC TCACCTATGG TGCTGCTAA GGCGTCAAA GATGTGTATA  
  
 2001 ATTGCGAAGA TGTGGCGTGT TACGGTGAAA ACCTGGCCTA TTTCCCTAAA  
 TAAGCGTTCT ACACCGCACA ATGCCACTTT TGGACCGGAT AAAGGGATTT  
  
 2051 GGGTTTATTG AGAATATGTT TTTCGTCTCA GCCAATCCCT GGGTGAGTTT  
 CCCAAATAAC TCTTATACAA AAAGCAGAGT CGGTTAGGGA CCCACTCAAA  
  
 2101 CACCAGTTT GATTTAACG TAGCCAATAT GGACAACCTTC TTGCCCCCG  
 GTGGTCAAAA CTAAATTGTC ATCGGTTATA CCTGTTGAAG AAGCGGGGC  
  
 2151 TTTTCACTAT GGGCAAATAT TATACGCAAG GCGACAAGGT GCTGATGCCG  
 AAAAGTGATA CCCGTTATA ATATGCGTTC CGCTGTTCCA CGACTACGGC  
  
 2201 CTGGCGATTG AGGTTCATCA TGCCGTTGT GATGGCTTCC ATGTCGGCAG  
 GACCGCTAAG TCCAAGTAGT ACGGCAAACA CTACCGAAGG TACAGCCGTC  
  
 2251 AATGCTTAAT GAATTACAAC AGTACTGCGA TGAGTGGCAG GGCGGGGCGT  
 TTACGAATTA CTTAATGTTG TCATGACGCT ACTCACCGTC CCGCCCCGCA  
  
 2301 AATTTTTTA AGGCAGTTAT TGGTGCCCTT AAACGCCTGG TGCTAGCCTG  
 TTAAAAAAAT TCCGTCATA ACCACGGAA TTTGCGGACC ACGATCGGAC  
  
 2351 AGGCCAGTTT GCTCAGGCTC TCCCCGTGGA GGTAAATAATT GCTCGACCGA  
 TCCGGTCAAA CGAGTCCGAG AGGGGCACCT CCATTATTAA CGAGCTGGCT  
  
 2401 TAAAAGCGGC TTCCTGACAG GAGGCCGTTT TGTTTGCAAG CCCACCTCAA  
 ATTTTCGCCG AAGGACTGTC CTCCGGCAAAC AAAAACGTC GGGTGGAGTT  
  
 2451 CGCAATTAAT GTGAGTTAGC TCACTCATTA GGCACCCAG GCTTTACACT  
 GCGTTAATTA CACTCAATCG AGTGAGTAAT CCGTGGGGTC CGAAATGTGA  
  
 2501 TTATGCTTCC GGCTCGTATG TTGTGTGGAA TTGTGAGCGG ATAACAATTT  
 AATACGAAGG CCGAGCATAAC AACACACCTT AACACTCGCC TATTGTTAAA

18/39

2551 CACACAGGAA ACAGCTATGA CCATGATTAC GAATTCCTAG ATAACGAGGG  
GTGTGTCCTT TGTCGATACT GGTACTAATG CTTAAAGATC TATTGCTCCC

2601 CAAAAAAATGA AAAAGACAGC TATCGCGATT GCAGTGGCAC TGGCTGGTTT  
GTTTTTTACT TTTCTGTG ATAGCGCTAA CGTCACCGTG ACCGACCAAA

2651 CGCTACCGTA GCGCAGGCCG ACTACAAAGA TGTCGACGCC GGTGGTCGGA  
GCGATGGCAT CGCGTCCGGC TGATGTTCT ACAGCTGCGG CCACCAGCCT

2701 TCGCCCCGGCT AGAGGAAAAA GTGAAAACCT TGAAAGCGCA AAACCTCCGAG  
AGCGGGCCGA TCTCCTTTT CACTTTGGA ACTTCGCGT TTTGAGGCTC

2751 CTGGCGTCCA CGGCCAACAT GCTCAGGGAA CAGGTGGCAC AGCTTAAACA  
GACCGCAGGT GCCGGTTGTA CGAGTCCCTT GTCCACCGTG TCGAATTGT

## EcoRI

2801 GAAAGTCATG AACCACGGTG GTGCCAATT CAATGCTGGC GCGGGCTCTG  
CTTTCAGTAC TTGGTGCCAC CACGGCTAA GTTACGACCG CCGCCGAGAC

2851 GTGGTGGTTC TGGTGGCGGC TCTGAGGGTG GTGGCTCTGA GGGTGGCGGT  
CACCACCAAG ACCACCGCCG AGACTCCCAC CACCGAGACT CCCACCGCCA

2901 TCTGAGGGTG GCGGCTCTGA GGGAGGCGGT TCCGGTGGTG GCTCTGGTTC  
AGACTCCCAC CGCCGAGACT CCCTCCGCCA AGGCCACAC CGAGACCAAG

2951 CGGTGATTT GATTATGAAA AGATGGCAA CGCTAATAAG GGGGCTATGA  
GCCACTAAA CTAATACTTT TCTACCGTTT GCGATTATTC CCCCCGATACT

3001 CCGAAAATGC CGATGAAAAC GCGCTACAGT CTGACGCTAA AGGCAAACCTT  
GGCTTTACG GCTACTTTG CGCGATGTCA GACTGCGATT TCCGTTGAA

## ClaI

3051 GATTCTGTCG CTACTGATTA CGGTGCTGCT ATCGATGGTT TCATTGGTA  
CTAAGACAGC GATGACTAAT GCCACGACGA TAGCTACCAA AGTAACCACT

3101 CGTTTCCGGC CTTGCTAATG GTAATGGTGC TACTGGTGAT TTTGCTGGCT  
GCAAAGGCCG GAACGATTAC CATTACCAAG ATGACCACTA AAACGACCGA

3151 CTAATTCCA AATGGCTAA GTCGGTGACG GTGATAATTG ACCTTAATG  
GATTAAGGGT TTACCGAGTT CAGCCACTGC CACTATTAAG TGAAATTAC

3201 AATAATTCC GTCAATATTT ACCTTCCCTC CCTCAATCGG TTGAATGTCG  
TTATTAAAGG CAGTTATAAA TGGAAGGGAG GGAGTTAGCC AACTTACAGC

3251 CCCTTTGTC TTTAGCGCTG GTAAACCATA TGAATTTCT ATTGATTGTG  
GGGAAACAG AAATCGCGAC CATTGGTAT ACTTAAAAGA TAACTAACAC

3301 ACAAAATAAA CTTATTCCGT GGTGTCTTTG CGTTTCTTTT ATATGTTGCC  
TGTTTTATTT GAATAAGGCA CCACAGAAC GCAAAGAAAA TATACAACGG

19/39

3351 ACCTTTATGT ATGTATTTTC TACGTTGCT AACATACTGC GTAATAAGGA  
TGGAAATACA TACATAAAAG ATGCAAACGA TTGTATGACG CATTATTCCCT

HindIII

3401 GTCTTGATAA GCTTCGAGAA ATTCACCTCG AAAGCAAGCT GATAAAACCGA  
CAGAACTATT CGAAGCTCTT TAAGTGGAGC TTTCGTTCGA CTATTGGCT

3451 TACAATTAAA GGCTCCTTTT GGAGCCCTTTT TTTTGGAGA ATTAATTCAA  
ATGTTAATT CCGAGGAAAA CCTCGGAAAA AAAAACCTCT TAATTAAGTT

3501 TCATGCCAGT TCTTTGGGT ATTCCGTTAT TATTGCGTTT CCTCGGTTTC  
AGTACGGTCA AGAAAACCCA TAAGGCAATA ATAACGCAA GGAGCCAAAG

3551 CTTCTGGTAA CTTTGTTCGG CTATCTGCTT ACTTTCCCTA AAAAGGGCTT  
GAAGACCATT GAAACAAGCC GATAGACGAA TGAAAGGAAT TTTTCCGAA

3601 CGGTAAGATA GCTATTGCTA TTTCATTGTT TCTTGCTCTT ATTATTGGGC  
GCCATTCTAT CGATAACGAT AAAGTAACAA AGAACGAGAA TAATAACCCG

3651 TTAACTCAAT TCTTGTGGGT TATCTCTCTG ATATTAGCGC ACAATTACCC  
AATTGAGTTA AGAACACCCA ATAGAGAGAC TATAATCGCG TGTAAATGGG

3701 TCTGATTTTG TTCAGGGCGT TCAGTTAATT CTCCCGTCTA ATGCGCTTCC  
AGACTAAAAC AAGTCCCGCA AGTCAATTAA GAGGGCAGAT TACCGAAGG

3751 CTGTTTTAT GTTATTCTCT CTGTAAGGC TGCTATTTTC ATTTTGACG  
GACAAAAATA CAATAAGAGA GACATTCCG ACGATAAAAG TAAAAACTGC

3801 TAAACAAAAA AATCGTTCT TATTTGGATT GGGATAAATA AATATGGCTG  
AATTGTTTT TTAGCAAAGA ATAAACCTAA CCCTATTTAT TTATACCGAC

3851 TTTATTTGT AACTGGCAA TTAGGCTCTG GAAAGACGCT CGTTAGCGTT  
AAATAAAACA TTGACCGTTT AATCCGAGAC CTTCTGCGA GCAATCGCAA

3901 GGTAAAGATTC AGGATAAAAT TGTAGCTGGG TGCAAAATAG CAACTAATCT  
CCATTCTAAG TCCTATTTA ACATCGACCC ACGTTTTATC GTGATTAGA

3951 TGATTTAAGG CTTCAAAACC TCCCGCAAGT CGGGAGGTTTC GCTAAAACGC  
ACTAAATTCC GAAGTTTTGG AGGGCGTTCA GCCCTCCAAG CGATTTGCG

4001 CTCGCGTTCT TAGAATACCG GATAAGCCTT CTATTTCTGA TTTGCTTGCT  
GAGCGCAAGA ATCTTATGGC CTATTCGAA GATAAAGACT AAACGAACGA

4051 ATTGGTCGTG GTAATGATTC CTACGACGAA AATAAAAACG GTTTGCTTGT  
TAACCAGCAC CATTACTAAG GATGCTGCTT TTATTTTGC CAAACGAACA

4101 TCTTGATGAA TGCAGTACTT GGTTAATAC CCGTCATGG AATGACAAGG  
AGAACTACTT ACGCCATGAA CCAAATTATG GGCAAGTACC TTACTGTTCC

20/39

4151 AAAGACAGCC GATTATTGAT TGGTTCTTC ATGCTCGTAA ATTGGGATGG  
 TTTCTGTCGG CTAATAACTA ACCAAAGAAG TACGAGCATT TAACCCTTAC  
  
 4201 GATATTATTT TTCTTGTCA GGATTATCT ATTGTTGATA AACAGGCGCG  
 CTATAATAAA AAGAACAAAGT CCTAAATAGA TAACAACAT TTGTCCGCG  
  
 4251 TTCTGCATTA GCTGAACACG TTGTTTATTG TCGCCGTCTG GACAGAATTA  
 AAGACGTAAT CGACTTGTGC AACAAATAAC AGCGGCAGAC CTGTCTTAAT  
  
 4301 CTTTACCCCTT TGCGGCAC T TATATTCTC TTGTTACTGG CTCAAAATG  
 GAAATGGAA ACAGCCGTGA AATATAAGAG AACAAATGACC GAGTTTTAC  
  
 4351 CCTCTGCCTA AATTACATGT TGGTGTGTT AAATATGGTG ATTCTCAATT  
 GGAGACGGAT TTAATGTACA ACCACAACAA TTTATACAC TAAGAGTTAA  
  
 4401 AAGCCCTACT GTTGAGCGTT GGCTTATAC TGGTAAGAAT TTATATAACG  
 TTCGGGATGA CAACTCGCAA CCGAAATATG ACCATTCTTA AATATATTGC  
  
 4451 CATATGACAC TAAACAGGCT TTTCCAGTA ATTATGATTC AGGTGTTTAT  
 GTATACTGTG ATTTGTCCGA AAAAGGTCA TAACTAAAG TCCACAAATA  
  
 4501 TCATATTAA CCCCTTATT TACACACGGT CGGTATTTCA AACCAATTAAA  
 AGTATAAAATT GGGAAATAAA TAGTGTGCCA GCCATAAAAGT TTGGTAATT  
  
 4551 TTTAGGTCAAG AAGATGAAAT TAACTAAAT ATATTTGAA AAGTTTCTC  
 AAATCCAGTC TTCTACTTTA ATTGATTAA TATAAACTTT TTCAAAAGAG  
  
 4601 GCGTTCTTG TCTTGCATA GGATTGCA T CAGCATTAC ATATAGTTAT  
 CGCAAGAAC AGAACGCTAT CCTAAACGTA GTCGTAAATG TATATCAATA  
  
 4651 ATAACCCAAAC CTAAGCCGGA GGTTAAAAG GTAGTCTCTC AGACCTATGA  
 TATTGGGTG GATTGGCCT CCAATTTC CATCAGAGAG TCTGGATACT  
  
 4701 TTTTGATAAA TTCACTATTG ACTCTTCTCA GCGTCTTAAT CTAAGCTATC  
 AAAACTATT AAGTGATAAC TGAGAAGAGT CGCAGAATTA GATTGATAG  
  
 4751 GCTATGTTT CAAGGATTCT AAGGGAAAAT TAATTAATAG CGACGATTAA  
 CGATACAAA GTTCCCTAAGA TTCCCTTTA ATTAATTATC GCTGCTAAAT  
  
 4801 CAGAAGCAAG GTTATTCCAT CACATATATT GATTTATGTA CTGTTCAAT  
 GTCTTCGTTCAATAAGGTA GTGTATATAA CTAAAATACAT GACAAAGTTA  
  
 4851 TAAAAAAAGGT AATTCAAATG AAATTGTTAA ATGTAATTAA TTTTGTTC  
 ATTTTTCCA TTAAGTTAC TTTAACAAATT TACATTAATT AAAACAAAAG  
  
 4901 TTGATGTTG TTTCATCATC TTCTTTGCT CAAGTAATTG AAATGAATAA  
 AACTACAAAC AAAGTAGTAG AAGAAAACGA GTTCATTAAC TTTACTTATT  
  
 4951 TTCCGCTCTG CGCGATTCG TGACTTGGTA TTCAAAGCAA ACAGGTGAAT  
 AAGCGGAGAC GCGCTAAAGC ACTGAACCAT AAGTTCGTT TGTCCACTTA

21/39

5001 CTGTTATTGT CTCACCTGAT GTTAAAGGTA CAGTGACTGT ATATTCCTCT  
 GACAATAACA GAGTGGACTA CAATTCCAT GTCACTGACA TATAAGGAGA  
 5051 GACGTTAACG CTGAAAATTG ACGCAATTTC TTTATCTCTG TTTTACGTGC  
 CTGCAATTG GACTTTAAA TGCGTTAAAG AAATAGAGAC AAAATGCACG  
 5101 TAATAATTGATGTTGTTG GCTCAATTCC TTCCATAATT CAGAAATATA  
 ATTATTAAAA CTATACCAAC CGAGTTAAGG AAGGTATTAA GTCTTTATAT  
 5151 ACCCAAATAG TCAGGATTAT ATTGATGAAT TGCCATCATC TGATATTGAG  
 TGGGTTTATC AGTCTAATA TAACTACTTA ACGGTAGTAG ACTATAAGTC  
 5201 GAATATGATG ATAATTCCGC TCCTTCTGGT GGTTTCTTTG TTCCGCAAAA  
 CTTATACTAC TATTAAGGCG AGGAAGACCA CCAAAGAAC AAGGCGTTTT  
 5251 TGATAATGTT ACTCAAACAT TTAAAATTAA TAACGTTCGC GCAAAGGATT  
 ACTATTACAA TGAGTTTGTA AATTTAATT ATTGCAAGCG CGTTCCCTAA  
 5301 TAATAAGGGT TGTAGAATTG TTTGTTAAAT CTAATACATC TAAATCCTCA  
 ATTATTCCCA ACATCTAAC AAACAATTAA GATTATGTAG ATTTAGGAGT  
 5351 AATGTATTAT CTGTTGATGG TTCTAACTTA TTAGTAGTTA GCGCCCTAA  
 TTACATAATA GACAACCTACC AAGATTGAAT AATCATCAAT CGCGGGGATT  
 5401 AGATATTTA GATAACCTTC CGCAATTCT TTCTACTGTT GATTGCCAA  
 TCTATAAAAT CTATTGGAAG GCGTTAAAGA AAGATGACAA CTAAACGGTT  
 5451 CTGACCAGAT ATTGATTGAA GGATTAATT TCGAGGTTCA GCAAGGTGAT  
 GACTGGTCTA TAACTAACTT CCTAATTAAA AGCTCCAAGT CGTTCCACTA  
 5501 GCTTAGATT TTTCTTTGC TGCTGGCTCT CAGCGCGCA CTGTTGCTGG  
 CGAAATCTAA AAAGGAAACG ACGACCGAGA GTCGCGCCGT GACAACGACC  
 5551 TGGTGTAAAT ACTGACCGTC TAACCTCTGT TTTATCTTCT GCGGGTGGTT  
 ACCACAATTAA TGACTGGCAG ATTGGAGACA AAATAGAAGA CGCCACCAA  
 5601 CGTCGGTAT TTTAACCGGC GATGTTTAG GGCTATCAGT TCGCGCATTAA  
 GCAAGCCATA AAAATTGCCG CTACAAAATC CCGATAGTCA AGCGCGTAAT  
 5651 AAGACTAATA GCCATTCAAA AATATTGTCT GTGCCTCGTA TTCTTACGCT  
 TTCTGATTAT CGGTAAGTTT TTATAACAGA CACGGAGCAT AAGAATGCGA  
 5701 TTCAGGTCAG AAGGGTTCTA TTTCTGTTGG CCAGAATGTC CCTTTTATTA  
 AAGTCCAGTC TTCCCAAGAT AAAGACAACC GGTCTTACAG GGAAAATAAT  
 5751 CTGGTCGTGT AACTGGTGAA TCTGCCAATG TAAATAATCC ATTCAGACG  
 GACCAGCACA TTGACCACCT AGACGGTTAC ATTATTAGG TAAAGTCTGC  
 5801 GTTGAGCGTC AAAATGTTGG TATTCTATG AGTGTGTTTC CCGTTGCAAT  
 CAACTCGCAG TTTTACAACC ATAAAGATAC TCACAAAAG GGCAACGTTA

22/39

5851 GGCTGGCGGT AATATTGTT TAGATATAAC CAGTAAGGCC GATAGTTGA  
 CCGACCGCCA TTATAACAAA ATCTATATTG GTCATTCCGG CTATCAAACCT  
 5901 GTTCTTCTAC TCAGGCAAGT GATGTTATTA CTAATCAAAG AAGTATTGCG  
 CAAGAAGATG AGTCCGTTCA CTACAATAAT GATTAGTTTC TTCATAACGC  
 5951 ACAACGGTTA ATTTGCGTGA TGGTCAGACT CTTTGCTCG GTGGCCTCAC  
 TGTTGCCAAT TAAACGCACT ACCAGTCTGA GAAAACGAGC CACCGGAGTG  
 6001 TGATTACAAA AACACTTCTC AAGATTCTGG TGTGCCGTTTC CTGTCTAAA  
 ACTAATGTTT TTGTGAAGAG TTCTAAGACC ACACGGCAAG GACAGATTTT  
 6051 TCCCTTTAAT CGGCCTCCTG TTTAGCTCCC GTTCTGATTC TAACGAGGAA  
 AGGGAAATTA GCCGGAGGAC AAATCGAGGG CAAGACTAAG ATTGCTCCTT  
 6101 AGCACGTTGT ACGTGCTCGT CAAAGCAACC ATAGTACGCG CCCTGTAGCG  
 TCGTGCAACA TGCACGAGCA GTTTCGTTGG TATCATGCGC GGGACATCGC  
 6151 GCGCATTAAAG CGCGGCGGGT GTGGTGGTTA CGCGCAGCGT GACCGCTACA  
 CGCGTAATTG GCGCCGCCA CACCACCAAT GCGCGTCGCA CTGGCGATGT  
 6201 CTTGCCAGCG CCCTAGCGCC CGCTCCTTTC GCTTTCTTCC CTTCTTTCT  
 GAACGGTCGC GGGATCGCGG GCGAGGAAAG CGAAAGAAGG GAAGGAAAGA

BamHI

-----

6251 CGCCACGTTTC TCCGGCTTTC CCCGTCAAGC TCTAAATCGG GGGATCCCTT  
 GCGGTGCAAG AGGCCGAAAG GGGCAGTTCG AGATTTAGCC CCCTAGGGAA  
 6301 TAGGGTTCG ATTTAGTGCT TTACGGCACC TCGACCTCCA AAAACTTGAT  
 ATCCCAAGGC TAAATCACGA AATGCCGTGG AGCTGGAGGT TTTGAACTA  
 6351 TTGGGTGATG GTTCACGTAG TGGGCCATCG CCCTGATAGA CGGTTTTCG  
 AACCCACTAC CAAGTGCATC ACCCGGTAGC GGGACTATCT GCCAAAAAGC  
 6401 CCCTTGACG TTGGAGTCCA CGTTCTTAA TAGTGGACTC TTGTTCCAAA  
 GGGAAACTGC AACCTCAGGT GCAAGAAATT ATCACCTGAG AACAAAGGTTT  
 6451 CTGGAACAAAC ACTCACAAC TAACTCGGCCT ATTCTTTGA TTTATAAGGA  
 GACCTGTTG TGAGTGTGA TTGAGCCGGA TAAGAAAAC AAATATTCCCT  
 6501 TTTTGTCAT TTTCTGCTTA CTGGTTAAAA AATAAGCTGA TTTAACAAAT  
 AAAAACAGTA AAAGACGAAT GACCAATTTC TTATTCGACT AAATTGTTA  
 6551 ATTTAACGCG AAATTTAACA AAACATTAAC GTTTACAATT TAAATATTTG  
 TAAATTCGCGC TTTAAATTGT TTGTAATTG CAAATGTTAA ATTTATAAAC  
 6601 CTTATACAAT CATCCTGTTT TTGGGGCTTT TCTGATTATC AACCGGGGTA  
 GAATATGTTA GTAGGACAAA AACCCCGAAA AGACTAATAG TTGGCCCCAT

23/39

ClaI

-----

6651 CATATGATTG ACATGCTAGT TTTACGATTA CCGTTCATCG ATTCTCTTGT  
GTATACTAAC TGTACGATCA AAATGCTAAT GGCAAGTAGC TAAGAGAAC

6701 TTGCTCCAGA CTTTCAGGTA ATGACCTGAT AGCCTTGTA GACCTCTCAA  
AACGAGGTCT GAAAGTCCAT TACTGGACTA TCGGAAACAT CTGGAGAGTT

6751 AAATAGCTAC CCTCTCCGGC ATGAATTAT CAGCTAGAAC GGTTGAATAT  
TTTATCGATG GGAGAGGCCG TACTTAAATA GTCGATCTTGT CCAACTTATA

6801 CATATTGACG GTGATTTGAC TGTCTCCGGC CTTTCTCACC CGTTTGAATC  
GTATAACTGC CACTAAACTG ACAGAGGCCG GAAAGAGTGG GCAAACCTAG

6851 TTTGCCTACT CATTACTCCG GCATTGCATT TAAAATATAT GAGGGTTCTA  
AACGGATGA GTAATGAGGC CGTAACGTAA ATTTTATATA CTCCCAAGAT

6901 AAAATTTTA TCCCTGCGTT GAAATTAAGG CTTCACCAAGC AAAAGTATTA  
TTTTAAAAAT AGGGACGCAA CTTTAATTCC GAAGTGGTCG TTTTCATAAT


6951 CAGGGTCATA ATGTTTTGG TACAACCGAT TTAGCTTAT GCTCTGAGGC  
GTCCCAGTAT TACAAAAACC ATGTTGGCTA AATCGAAATA CGAGACTCCG

7001 TTTATTGCTT AATTTGCTA ACTCTCTGCC TTGCTTGAC GATTTATTGG  
AAATAACGAA TTAAAACGAT TGAGAGACGG AACGAACATG CTAAATAACC

7051 ATGTT  
TACAA

24/39

Figure 4



25/39

HindIII

~~~~~

1 AGCTTCGAGA AATTCACCTC GAAAGCAAGC TGATAAACCG ATACAATTAA  
TCGAAGCTCT TTAAGTGGAG CTTTCGTTCG ACTATTTGGC TATGTTAATT

51 AGGCTCCTTT TGGAGCCTTT TTTTTGGAG AATTAATTCA ATCATGCCAG  
TCGGAGGAAA ACCTCGGAAA AAAAAACCTC TTAATTAAGT TAGTACGGTC

101 TTCTTTGGG TATTCCGTTA TTATTGCGTT TCCTCGGTTT CCTTCTGGTA  
AAGAAAACCC ATAAGGCAAT AATAACGCAA AGGAGCCAAA GGAAGACCAT

151 ACTTTGTTCG GCTATCTGCT TACTTTCCCTT AAAAAGGGCT TCGGTAAGAT  
TGAAACAAGC CGATAGACGA ATGAAAGGAA TTTTCCCGA AGCCATTCTA

201 AGCTATTGCT ATTCATTGCT TTCTTGCTCT TATTATTGGG CTTAACTCAA  
TCGATAACGA TAAAGTAACA AAGAACGAGA ATAATAACCC GAATTGAGTT

251 TTCTTGTTGGG TTATCTCTCT GATATTAGCG CACAATTACC CTCTGATTTT  
AAGAACACCC AATAGAGAGA CTATAATCGC GTGTTAATGG GAGACTAAAA

301 GTTCAGGGCG TTCAAGTTAAT TCTCCCGTCT AATGCGCTTC CCTGTTTTTA  
CAAGTCCCGC AAGTCAATTAA AGAGGGCAGA TTACGCGAAG GGACAAAAAT

351 TGTTATTCTC TCTGTAAAGG CTGCTATTTT CATTGGTAC GTTAAACAAA  
ACAATAAGAG AGACATTTC GACGATAAAA GTAAAAACTG CAATTGTTT

401 AAATCGTTTC TTATTTGGAT TGGGATAAAAT AAATATGGCT GTTATTTTG  
TTTAGCAAAG AATAAACCTA ACCCTATTAA TTTATACCGA CAAATAAAAC

451 TAACTGGCAA ATTAGGCTCT GGAAAGACGC TCGTTAGCGT TGGTAAGATT  
ATTGACCGTT TAATCCGAGA CCTTTCTGCG AGCAATCGCA ACCATTCTAA

501 CAGGATAAAA TTGTAGCTGG GTGCAAAATA GCAACTAATC TTGATTTAAG  
GTCCTATTTT AACATCGACC CACGTTTTAT CGTTGATTAG AACTAAATTC

551 GCTTCAAAAC CTCCCGCAAG TCGGGAGGTT CGCTAAAACG CCTCGCGTTC  
CGAAGTTTG GAGGGCGTTC AGCCCTCCAA GCGATTTGC GGAGCGCAAG

601 TTAGAATACC GGATAAGCCT TCTATTCTG ATTTGCTTGC TATTGGTCGT  
AATCTTATGG CCTATTCCGA AGATAAAAGAC TAAACGAACG ATAACCAGCA

651 GGTAATGATT CCTACGACGA AAATAAAAAC GGTTTGCTTG TTCTTGATGA  
CCATTACTAA GGATGCTGCT TTTATTTTG CCAAACGAAC AAGAACTACT

701 ATGCGGTACT TGGTTAATA CCCGTTCATG GAATGACAAG GAAAGACAGC  
TACGCCATGA ACCAAATTAT GGGCAAGTAC CTTACTGTTC CTTCTGTGCG

751 CGATTATTGA TTGGTTTCTT CATGCTCGTA AATTGGGATG GGATATTATT  
GCTAATAACT AACCAAAGAA GTACGAGCAT TTAACCCTAC CCTATAATAA

26/39

801 TTTCTTGTTC AGGATTTATC TATTGTTGAT AAACAGGCGC GTTCTGCATT  
AAAGAACAAAG TCCTAAATAG ATAACAACTA TTTGTCCGCG CAAGACGTAA

851 AGCTGAACAC GTTGTATTGTC GGACAGAATT ACTTTACCCCT  
TCGACTTGTG CAACAAATAA CAGCGGCAGA CCTGTCTTAA TGAAATGGGA

901 TTGTCGGCAC TTTATATTCT CTTGTTACTG GCTCAAAAT GCCTCTGCCT  
AACAGCCGTG AAATATAAGA GAACAATGAC CGAGTTTTA CGGAGACGGA

951 AAATTACATG TTGGTGTGTTG TAAATATGGT GATTCTCAAT TAAGCCCTAC  
TTTAATGTAC AACCACAACA ATTTATACCA CTAAGAGTTA ATTCGGGATG

1001 TGTTGAGCGT TGGCTTATA CTGGTAAGAA TTTATATAAC GCATATGACA  
ACAACTCGCA ACCGAAATAT GACCATTCTT AAATATATTG CGTATACTGT

1051 CTAAACAGGC TTTTCCAGT AATTATGATT CAGGTGTTA TTCATATTAA  
GATTGTCCG AAAAAGGTCA TTAATACTAA GTCCACAAAT AAGTATAAAAT

1101 ACCCCTTATT TATCACACGG TCGGTATTTC AAACCATTAA ATTTAGGTCA  
TGGGAATAA ATAGTGTGCC AGCCATAAAG TTTGGTAATT TAAATCCAGT

1151 GAAGATGAAA TTAACTAAAA TATATTTGAA AAAGTTTCT CGCGTTCTT  
CTTCTACTTT AATTGATTAA ATATAAACTT TTTCAAAAGA GCGCAAGAAA

1201 GTCTTGCAT AGGATTTGCA TCAGCATTAA CATATAGTTA TATAACCAA  
CAGAACGCTA TCCTAAACGT AGTCGTAAAT GTATATCAAT ATATTGGTT

1251 CCTAAGCCGG AGGTTAAAAA GGTAGTCTCT CAGACCTATG ATTTGATAA  
GGATTCGGCC TCCAATTAA CCATCAGAGA GTCTGGATAC TAAAACATT

1301 ATTCACTATT GACTCTTCTC AGCGTCTTAA TCTAAGCTAT CGCTATGTTT  
TAAGTGTAACTT CTGAGAAGAG TCGCAGAATT AGATTGATA GCGATACAAA

1351 TCAAGGATTC TAAGGGAAAA TTAATTAATA GCGACGATTT ACAGAACAA  
AGTTCTAAG ATTCCCTTTT AATTAATTAT CGCTGCTAAA TGTCTCGTT

1401 GGTTATTCCA TCACATATAT TGATTTATGT ACTGTTCAA TTAAAAAAGG  
CCAATAAGGT AGTGTATATA ACTAAATACA TGACAAAGTT AATTTTTCC

1451 TAATTCAAAT GAAATTGTTA AATGTAATTA ATTTGTTTT CTTGATGTTT  
ATTAAGTTA CTTAACAAAT TTACATTAAT TAAAACAAAA GAACTACAAA

1501 GTTTCATCAT CTTCTTTGC TCAAGTAATT GAAATGAATA ATTGCCTCT  
CAAAGTAGTA GAAGAAAACG AGTTCAATTAA CTTTACTTAT TAAGCGGAGA

1551 GCGCGATTTC GTGACTTGGT ATTCAAAGCA AACAGGTGAA TCTGTTATTG  
CGCGCTAAAG CACTGAACCA TAAGTTCGT TTGTCCACTT AGACAATAAC

1601 TCTCACCTGA TGTTAAAGGT ACAGTGAATG TATATTCTC TGACGTTAAG  
AGAGTGGACT ACAATTCCA TGTCAGTAC ATATAAGGAG ACTGCAATT

27/39

1651 CCTGAAAATT TACGCAATT CTTTATCTCT GTTTACGTG CTAATAATT GGACTTTAA ATGCGTTAAA GAAATAGAGA CAAAATGCAC GATTATTAAA

1701 TGATATGGTT GGCTCTAAC CTTCCATAAT TCAGAAATAT AACCCAAATA ACTATACCAA CCGAGATTAG GAAGGTATTA AGTCTTATA TTGGGTTTAT

1751 GTCAGGATTA TATTGATGAA TTGCCATCAT CTGATATTCA GGAATATGAT CAGTCCTAAT ATAACTAATT AACGGTAGTA GACTATAAGT CCTTATACTA

1801 GATAATTCCG CTCCTTCTGG TGGTTCTTT GTTCCGAAA ATGATAATGT CTATTAAGGC GAGGAAGACC ACCAAAGAAA CAAGCGTTT TACTATTACA

1851 TACTCAAACA TTTAAAATTAA ATAACGTTCG CGCAAAGGAT TTAATAAGGG ATGAGTTGT AAATTTAAT TATTGCAAGC GCGTTCTA AATTATTCCC

1901 TTGTAGAATT GTTGTTAAA TCTAATACAT CTAAATCCTC AAATGTATTA AACATCTAA CAAACAATT AGATTATGTA GATTTAGGAG TTTACATAAT

1951 TCTGTTGATG GTTCTAACCT ATTAGTAGTT AGCGCCCCTA AAGATATTTT AGACAACTAC CAAGATTGAA TAATCATCAA TCGCGGGGAT TTCTATAAAA

2001 AGATAACCTT CCGCAATTTC TTTCTACTGT TGATTTGCCA ACTGACCAGA TCTATTGGAA GGC GTTAAAG AAAGATGACA ACTAAACGGT TGACTGGTCT

2051 TATTGATTGA AGGATTAATT TTGAGGTTC AGCAAGGTGA TGCTTTAGAT ATAACTAACT TCCTAATTAA AAGCTCCAAG TCGTTCCACT ACGAAATCTA

2101 TTTTCCTTTG CTGCTGGCTC TCAGCGCGC ACTGTTGCTG GTGGTGTAA AAAAGGAAAC GACGACCGAG AGTCGCGCCG TGACAACGAC CACCACAATT

2151 TACTGACCGT CTAACCTCTG TTTTATCTTC TGCGGGTGGT TCGTTCGGTA ATGACTGGCA GATTGGAGAC AAAATAGAAG ACGCCCACCA AGCAAGCCAT

2201 TTTTTAACGG CGATGTTTTA GGGCTATCAG TTGCGCGCATT AAAGACTAAT AAAAATTGCC GCTACAAAAT CCCGATAGTC AAGCGCGTAA TTTCTGATTA

2251 AGCCATTCAA AAATATTGTC TGTGCCCTCGT ATTCTTACGC TTTCAGGTCA TCGGTAAGTT TTTATAACAG ACACGGAGCA TAAGAATGCG AAAGTCCAGT

2301 GAAGGGTTCT ATTCTGTTG GCCAGAATGT CCCTTTATT ACTGGTCGTG CTTCCAAGA TAAAGACAAC CGGTCTTACA GGGAAAATAA TGACCAGCAC

2351 TAACTGGTGA ATCTGCCAAT GTAAATAATC CATTTCAGAC AATTGAGCGT ATTGACCAACT TAGACGGTTA CATTATTAG GTAAAGTCTG TTAACTCGCA

2401 CAAAATGTG GTATTCTAT GAGTGTAAAA CCCGTTGCAA TGGCTGGCGG GTTTTACAAC CATAAAGATA CTCACAAAAA GGGCAACGTT ACCGACCGCC

2451 TAATATTGTT TTAGATATAA CCAGTAAGGC CGATAGTTG AGTTCTTCTA ATTATAACAA AATCTATATT GGTCAATTCCG GCTATCAAAC TCAAGAAGAT

28/39

2501 CTCAGGCAAG TGATGTTATT ACTAATCAA GAAGTATTGC GACAACGGTT  
 GAGTCCGTT ACTACAATAA TGATTAGTTT CTTCATAACG CTGTTGCCAA  
 2551 AATTGCGTG ATGGTCAGAC TCTTTGCTC GGTGGCCTCA CTGATTACAA  
 TTAAACGCAC TACCAGTCTG AGAAAACGAG CCACCGGAGT GACTAATGTT  
 2601 AAACACTTCT CAAGATTCTG GTGTGCCGTT CCTGTCTAAA ATCCCTTTAA  
 TTTGTGAAGA GTTCTAAGAC CACACGGCAA GGACAGATT TAGGGAAATT  
 2651 TCGGCCTCCT GTTAGCTCC CGTTCTGATT CTAACGAGGA AAGCACGTTG  
 AGCCGGAGGA CAAATCGAGG GCAAGACTAA GATTGCTCCT TTCGTGCAAC  
 2701 TACGTGCTCG TCAAAGCAAC CATAGTACGC GCCCTGTAGC GGCGCATTAA  
 ATGCACGAGC AGTTTCGTTG GTATCATGCG CGGGACATCG CCGCGTAATT  
 2751 GCGCGGCCGGG TGTGGTGGTT ACGCGCAGCG TGACCGCTAC ACTTGCCAGC  
 CGCGCCGCC ACACCACCAA TGCGCGTCGC ACTGGCGATG TGAACGGTCG  
 2801 GCCCTAGCGC CCGCTCCTT CGCTTCTTC CCTTCCTTTC TCGCCACGTT  
 CGGGATCGCG GGCGAGGAAA GCGAAAGAAG GGAAGGAAAG AGCGGTGCAA

BamHI

2851 CTCCGGCTTT CCCCGTCAAG CTCTAAATCG GGGGATCCCT TTAGGGTTCC  
 GAGGCCGAAA GGGGCAGTTC GAGATTAGC CCCCTAGGGA AATCCAAGG  
 2901 GATTTAGTGC TTTACGGCAC CTCGACCTCC AAAAACTTGA TTTGGGTGAT  
 CTAATCACG AAATGCCGTG GAGCTGGAGG TTTTGAACT AAACCCACTA  
 2951 GGTTCACGTA GTGGGCCATC GCCCTAATAG ACGGTTTTC GCCCTTGAC  
 CCAAGTGCAT CACCCGGTAG CGGGATTATC TGCCAAAAG CGGGAAACTG  
 3001 GTTGGAGTCC ACGTTCTTA ATAGTGGACT CTTGTTCCAA ACTGGAACAA  
 CAACCTCAGG TGCAAGAAAT TATCACCTGA GAACAAGGTT TGACCTTGT  
 3051 CACTCAACCC TATCTCGGTC TATTCTTTG ATTTATAAGG GATTTGCCG  
 GTGAGTTGGG ATAGAGCCAG ATAAGAAAAC TAAATATTCC CTAAAACGGC  
 3101 ATTTCGGCCT ATTGGTTAAA AAATGAGCTG ATTTAACAAA AATTTAACGC  
 TAAAGCCGGA TAACCAATT TTTACTCGAC TAAATTGTT TTAAATTGCG  
 3151 GAATTTAAC AAAATATTAA CGTTTACAAT TAAATATT GCTTACCAA  
 CTTAAAATTG TTTTATAATT GCAAATGTTA AATTTATAAA CGAATATGTT  
 3201 TCTTCCTGTT TTTGGGCTT TTCTGATTAT CAACCGGGGT ACATATGATT  
 AGAAGGACAA AAACCCGAA AAGACTAATA GTTGGCCCCA TGTATACTAA

ClaI

3251 GACATGCTAG TTTTACGATT ACCGTTCATC GATTCTCTTG TTTGCTCCAG  
 CTGTACGATC AAAATGCTAA TGGCAAGTAG CTAAGAGAAC AAACGAGGTC

29/39

3301 ACTCTCAGGC AATGACCTGA TAGCCTTTT AGACCTCTCA AAAATAGCTA  
 TGAGAGTCCG TTACTGGACT ATCGGAAAAA TCTGGAGAGT TTTTATCGAT  
 3351 CCCTCTCCGG CATGAATTAA TCAGCTAGAA CGGTTGAATA TCATATTGAT  
 GGGAGAGGCC GTACTTAAAT AGTCGATCTT GCCAACTTAT AGTATAACTA  
 3401 GGTGATTGTA CTGTCTCCGG CCTTTCTCAC CCGTTGAAT CTTTACCTAC  
 CCACTAAACT GACAGAGGCC GGAAAGAGTG GGCAAACCTTA GAAATGGATG  
 3451 ACATTACTCA GGCATTGCAT TTAAAATATA TGAGGGTTCT AAAAATTTT  
 TGTAATGAGT CCGTAACGTA AATTTATAT ACTCCCAAGA TTTTAAAAAA  
 3501 ATCCTTGCCT TGAAATAAAAG GCTTCTCCCG CAAAAGTATT ACAGGGTCAT  
 TAGGAACGCA ACTTTATTTC CGAAGAGGCC GTTTCATAA TGTCCCAGTA  
 3551 AATGTTTTG GTACAACCGA TTTAGCTTTA TGCTCTGAGG CTTTATTGCT  
 TTACAAAAAC CATGTTGGCT AAATCGAAAT ACGAGACTCC GAAATAACGA  
 3601 TAATTTGCT AATTCTTGC CTTGCCCTGTA TGATTATTG GATGTTAACG  
 ATTAAAACGA TTAAGAAACG GAACGGACAT ACTAAATAAC CTACAATTGC  
 3651 CTACTACTAT TAGTAGAATT GATGCCACCT TTTCAGCTCG CGCCCCAAAT  
 GATGATGATA ATCATCTTAA CTACGGTGGAA AAAGTCGAGC GCGGGGTTA  
 3701 GAAAATATAG CTAACACAGGT TATTGACCCT TTGCGAAATG TATCTAATGG  
 CTTTTATATC GATTGTCCA ATAACGTGGTA AACGCTTAC ATAGATTACC  
 3751 TCAAACCTAAA TCTACTCGTT CGCAGAATTG GGAATCAACT GTTACATGGA  
 AGTTTGATTT AGATGAGCAA GCGTCTTAAC CCTTAGTTGA CAATGTACCT  
 3801 ATGAAACTTC CAGACACCGT ACTTTAGTTG CATATTAAA ACATGTTGAG  
 TACTTTGAAG GTCTGTGGCA TGAAATCAAC GTATAAATT TGTCACACTC  
 3851 CTACAGCACC AGATCCAGCA ATTAAGCTCT AAGCCATCCG CAAAATGAC  
 GATGTCGTGG TCTAGGTCGT TAATTGAGA TTCGGTAGGC GTTTTACTG  
 3901 CTCTTATCAA AAGGAGCAAT TAAAGGTACT CTCTAATCCT GACCTGTTGG  
 GAGAAATAGTT TTCCTCGTTA ATTTCCATGA GAGATTAGGA CTGGACAAACC  
 3951 AGTTTGCTTC CGGTCTGGTT CGCTTGAAG CTCGAATTAA AACCGGATAT  
 TCAAACGAAG GCCAGACCAA GCGAAACTTC GAGCTTAATT TTGCGCTATA  
 4001 TTGAAGTCTT TCGGGCTTCC TCTTAATCTT TTTGATGCAA TCCGCTTGC  
 AACCTCAGAA AGCCCGAAGG AGAATTAGAA AAAACTACGTT AGGCAGAACG  
 4051 TTCTGACTAT AATAGTCAGG GTAAAGACCT GATTTTGAT TTATGGTCAT  
 AAGACTGATA TTATCAGTCC CATTCTGGAA CTAAAAACTA AATACCAAGTA  
 4101 TCTCGTTTC TGAACGTGTT AAAGCATTG AGGGGGATTG AATGAATATT  
 AGAGCAAAAG ACTTGACAAA TTTCGTAAAC TCCCCCTAAG TTACTTATAAA

30/39

4151 TATGACGATT CCGCAGTATT GGACGCTATC CAGTCTAAC ATTTTACTAT  
 ATACTGCTAA GGCATCAA CCTGCGATAG GTCAGATTTG TAAAATGATA  
 4201 TACCCCCCTCT GGCAAAACTT CTTTGCAAA AGCCTCTCGC TATTTTGTT  
 ATGGGGGAGA CCGTTTGAA GAAAACGTTT TCGGAGAGCG ATAAAAACAA  
 4251 TTTATCGTCG TCTGGTAAAC GAGGGTTATG ATAGTGTGTC TCTTACTATG  
 AAATAGCAGC AGACCATTG CTCCCAATAC TATCACAAACG AGAATGATAAC  
 4301 CCTCGTAATT CCTTTGGCG TTATGTATCT GCATTAGTTG AATGTGGTAT  
 GGAGCATTAA GGAAAACCGC AATACATAGA CGTAATCAAC TTACACCATA  
 4351 TCCTAAATCT CAACTGATGA ATCTTCTAC CTGTAATAAT GTGTTCCGT  
 AGGATTTAGA GTTGACTACT TAGAAAGATG GACATTATTA CAACAAGGCA  
 4401 TAGTTCGTTT TATTAACGTA GATTTTCTT CCCAACGTCC TGACTGGTAT  
 ATCAAGCAAA ATAATTGCAT CTAAAAAGAA GGGTTGCAGG ACTGACCATA  
 4451 AATGAGCCAG TTCTTAAAAT CGCATAAGGT AATTACAAT GATTAAAGTT  
 TTACTCGTC AAGAATTAA GCGTATTCCA TTAAGTGTAA CTAATTCAA  
 4501 GAAATTAAAC CATCTCAAGC GCAATTCACT ACCCGTTCTG GTGTTCTCG  
 CTTTAATTG GTAGAGTTCG CGTTAAGTGA TGGGCAAGAC CACAAAGAGC  
 4551 TCAGGGCAAG CCTTATTACAC TGAATGAGCA GCTTTGTTAC GTTGATTTGG  
 AGTCCCGTTC GGAATAAGTG ACTTACTCGT CGAAACAATG CAACTAAACC  
 4601 GTAATGAATA TCCGGTGCTT GTCAAGATTA CTCTTGATGA AGGTCAAGCCA  
 CATTACTTAT AGGCCACGAA CAGTTCTAAT GAGAACTACT TCCAGTCGGT  
 4651 GCCTATGCCTC CTGGTCTGTA CACCGTGCAT CTGTCCTCGT TCAAAGTTGG  
 CGGATACGCG GACCAGACAT GTGGCACGTA GACAGGAGCA AGTTCAACC  
 4701 TCAGTTCGGT TCTCTTATGA TTGACCGTCT GCGCCTCGTT CCGGCTAAGT  
 AGTCAAGCCA AGAGAATACT AACTGGCAGA CGCGGAGCAA GGCGGATTCA  
 4751 AACATGGAGC AGGTCGCGGA TTTCGACACA ATTTATCAGG CGATGATACA  
 TTGTACCTCG TCCAGCGCT AAAGCTGTGT TAAATAGTCC GCTACTATGT  
 4801 AATCTCCGTT GTACTTTGTT TCGCGCTTGG TATAATCGCT GGGGGTCAAA  
 TTAGAGGCAA CATGAAACAA AGCGCGAACC ATATTAGCGA CCCCCAGTTT  
 4851 GATGAGTGTGTT TTAGTGTATT CTTTCGCTC TTTCGTTTA GGTTGGTGCC  
 CTACTCACAA AATCACATAA GAAAGCGGAG AAAGCAAAAT CCAACCACGG  
 4901 TTCGTAGTGG CATTACGTAT TTTACCCGTT TAATGGAAAC TTCCATGC  
 AAGCATCACC GTAATGCATA AAATGGCAA ATTACCTTG AAGGAGTACG  
 4951 GTAAGTCTTT AGTCCTCAAA GCCTCCGTAG CCGTTGCTAC CCTCGTTCCG  
 CATTCAAGAAA TCAGGAGTTT CGGAGGCATC GGCAACGATG GGAGCAAGGC

31/39

5001 ATGCTGTCTT TCGCTGCTGA GGGTGACGAT CCCGCAAAAG CGGCCTTGAGACAGAA AGCGACGACT CCCACTGCTA GGGCGTTTC GCGGAAACT

5051 CTCCCTGCAA GCCTCAGCGA CCGAATATAT CGGTTATGCG TGGGCATGGAGGGACGTT CGGAGTCGCT GGCTTATATA GCCAATACGC ACCCGCTACC

5101 TTGTTGTCAT TGTCGGCGCA ACTATCGGT A TCAAGCTGTT TAAGAAATTCAACAACAGTA ACAGCCGCGT TGATAGCCAT AGTCGACAA ATTCTTTAAG

5151 ACCTCGAAAG CAAGCTGATA AAGGAGGTTT CTCGATCGAG ACGTTGGGTG TGGAGCTTTC GTTCGACTAT TTCCCTCCAAA GAGCTAGCTC TGCAACCCAC

5201 AGGTTCCAAC TTTCACCATA ATGAAATAAG ATCACTACCG GGCGTATTTT TCCAAGGTTG AAAGTGGTAT TACTTTATTC TAGTGATGGC CCCGATAAAAA

5251 TTGAGTTATC GAGATTTCA GGAGCTAAGG AAGCTAAAAT GGAGAAAAAA AACTCAATAG CTCTAAAAGT CCTCGATTCC TTTCGATTTA CCTCTTTTT

5301 ATCACTGGAT ATACCACCGT TGATATATCC CAATGGCATC GTAAAGAACATAGTGACCTA TATGGTGGCA ACTATATAGG GTTACCGTAG CATTCTTGT

5351 TTTTGAGGCA TTTCAGTCAG TTGCTCAATG TACCTATAAC CAGACCGTTC AAAACTCCGT AAAGTCAGTC AACGAGTTAC ATGGATATTG GTCTGGCAAG

5401 AGCTGGATAT TACGGCCTTT TTAAAGACCG TAAAGAAAAA TAAGCACAAG TCGACCTATA ATGCCGGAAA AATTCTGGC ATTTCTTTT ATTCTGTGTC

5451 TTTTATCCGG CCTTTATTCA CATTCTTGCC CGCCTGATGA ATGCTCATCC AAAATAGGCC GGAAATAAGT GTAAGAACGG GCGGACTACT TACGAGTAGG

5501 GGAGTTCCGT ATGGCAATGA AAGACGGTGA GCTGGTATA TGGGATAGTG CCTCAAGGCA TACCGTTACT TTCTGCCACT CGACCACTAT ACCCTATCAC

5551 TTCAACCTTG TTACACCGTT TTCCATGAGC AAACGTAAAC GTTTCATCG AAGTGGGAAAC AATGTGGCAA AAGGTACTCG TTTGACTTTG CAAAAGTAGC

5601 CTCTGGAGTG AATACCACGA CGATTTCCGG CAGTTTCTAC ACATATATTC GAGACCTCAC TTATGGTGT GCTAAAGGCC GTCAAAGATG TGTATATAAG

5651 GCAAGATGTG GCGTGTACG GTGAAAACCT GGCCTATTTCC CCTAAAGGGT CGTTCTACAC CGCACAAATGC CACTTTGGA CCGGATAAAAG GGATTCCCAC

5701 TTATTGAGAA TATGTTTTG GTCTCAGCCA ATCCCTGGGT GAGTTTCACC AATAACTCTT ATACAAAAAG CAGAGTCGGT TAGGGACCCA CTCAAAGTGG

5751 AGTTTGATT TAAACGTAGC CAATATGGAC AACTTCTTCG CCCCCGTTTCTAAAACCTAA ATTTGCATCG GTTATACCTG TTGAAGAACG GGGGGCAAA

5801 CACTATGGGC AAATATTATA CGCAAGGCCA CAAGGTGCTG ATGCCGCTGG GTGATACCCG TTTATAATAT GCGTTCCGCT GTTCCACGAC TACGGCGACC

32/39

5851 CGATTCAGGT TCATCATGCC GTTTGTGATG GCTTCCATGT CGGCAGAATG  
 GCTAAGTCCA AGTAGTACGG CAAACACTAC CGAAGGTACA GCCGTCTTAC  
  
 5901 CTTAATGAAT TACAACAGTA CTGCGATGAG TGGCAGGGCG GGGCGTAATT  
 GAATTACTTA ATGTTGTCAT GACGCTACTC ACCGTCCCGC CCCGCATTAA  
  
 5951 TTTTTAAGGC AGTTATTGGT GCCCTTAAAC GCCTGGTGCT AGCCTGAGGC  
 AAAAATTCCG TCAATAACCA CGGGAATTG CGGACCACGA TCGGACTCCG  
  
 6001 CAGTTTGCTC AGGCTCTCCC CGTGGAGGTA ATAATTGCTC GACCGATAAA  
 GTCAAACGAG TCCGAGAGGG GCACCTCCAT TATTAACGAG CTGGCTATTT  
  
 6051 AGCGGCTTCC TGACAGGAGG CCGTTTGTT TTGCAGCCCA CCTCAACGCA  
 TCGCCGAAGG ACTGTCCTCC GGCAAAACAA AACGTCGGGT GGAGTTGCGT  
  
 6101 ATTAATGTGA GTTAGCTCAC TCATTAGGCA CCCCAGGCTT TACACTTTAT  
 TAATTACACT CAATCGAGTG AGTAATCCGT GGGGTCCGAA ATGTGAAATA  
  
 6151 GCTTCCGGCT CGTATGTTGT GTGGAATTGT GAGCGGATAA CAATTACACA  
 CGAAGGCCGA GCATACAAACA CACCTTAACA CTCGCCTATT GTTAAAGTGT  
  
 6201 CAGGAAACAG CTATGACCAT GATTACGAAT TTCTAGATAA CGAGGGCAAA  
 GTCCTTGTC GATACTGGTA CTAATGCTTA AAGATCTATT GCTCCGTTT  
  
 6251 AAATGAAAAA GACAGCTATC GCGATTGCAG TGGCACTGGC TGGTTTCGCT  
 TTTACTTTT CTGTCGATAG CGCTAACGTC ACCGTGACCG ACCAAAGCGA  
  
 6301 ACCGTAGCGC AGGGCGACTA CAAAGATGTC GACTGTATTG TTTATCATGC  
 TGGCATCGCG TCCGGCTGAT GTTTCTACAG CTGACATAAC AAATAGTACG

## BamHI EcoRI

6351 TCATTATCTT GTGCTAAGT GTGGTGGTGG AGGATCCGAA TTCAATGCTG  
 AGTAATAGAA CAACGATTCA CACCACCAACC TCCTAGGCTT AAGTTACGAC  
  
 6401 GCGGCGGCTC TGGTGGTGGT TCTGGTGGCG GCTCTGAGGG TGGTGGCTCT  
 CGCCGCCGAG ACCACCAACC AGACCACCGC CGAGACTCCC ACCACCGAGA  
  
 6451 GAGGGTGGCG GTTCTGAGGG TGGCGGCTCT GAGGGAGGCG GTTCCGGTGG  
 CTCCCACCGC CAAGACTCCC ACCGCCGAGA CTCCCTCCGC CAAGGCCACC  
  
 6501 TGGCTCTGGT TCCGGTGATT TTGATTATGA AAAGATGGCA AACGCTAATA  
 ACCGAGACCA AGGCCACTAA AACTAATACT TTTCTACCGT TTGCGATTAT  
  
 6551 AGGGGGCTAT GACCGAAAAT GCCGATGAAA ACCCGCTACA GTCTGACGCT  
 TCCCCCGATA CTGGCTTTA CGGCTACTTT TGCGCGATGT CAGACTGCGA

33/39

ClaI

6601 AAAGGCAAAC TTGATTCTGT CGCTACTGAT TACGGTGCTG CTATCGATGG  
TTTCCGTTTG AACTAAGACA GCGATGACTA ATGCCACGAC GATAGCTACC

6651 TTTCATGGT GACGTTCCG GCCTTGCTAA TGGTAATGGT GCTACTGGTG  
AAAGTAACCA CTGCAAAGGC CGGAACGATT ACCATTACCA CGATGACCAC

6701 ATTTGCTGG CTCTAATTCC CAAATGGCTC AAGTCGGTGA CGGTGATAAT  
TAAAACGACC GAGATTAAGG GTTTACCGAG TTCAGCCACT GCCACTATTAA

6751 TCACCTTAA TGAATAATTT CCGTCAATAT TTACCTTCCC TCCCTCAATC  
AGTGGAAATT ACTTATTAAA GGCAGTTATA AATGGAAGGG AGGGAGTTAG

6801 GGTTGAATGT CGCCCTTTG TCTTGCGC TGGTAAACCA TATGAATTTT  
CCAACCTACA GCGGGAAAAC AGAAACCGCG ACCATTGGT ATACTAAAAA


6851 CTATTGATTG TGACAAAATA AACTTATTCC GTGGTGTCTT TGCGTTTCTT  
GATAACTAAC ACTGTTTTAT TTGAATAAGG CACCACAGAA ACGCAAAGAA

6901 TTATATGTTG CCACCTTTAT GTATGTATTT TCTACGTTG CTAACATACT  
AATATACAAC GGTGGAAATA CATACTAAA AGATGCAAAC GATTGTATGA

HindIII

6951 GCGTAATAAG GAGTCTTGAT A  
CGCATTATTC CTCAGAACTA T


34/39

**Figure 5**

35/39

**Figure 6**

**M SIP Polyphage transductants transf.**




36/39


**Figure 7**

| dilution factor |              | transductants         |                   |
|-----------------|--------------|-----------------------|-------------------|
| pep3/p75ICD     |              | jun/p75ICD (t.u./ml)* |                   |
| 1               | pos. control | -                     | $6 \times 10^5$   |
| -               | neg. control | 1                     | 0                 |
| 1               |              | $10^2$                | $1.2 \times 10^4$ |
|                 |              | $10^3$                | $8.6 \times 10^2$ |
|                 |              | $10^4$                | $1.2 \times 10^2$ |
|                 |              | $10^5$                | $12^*$            |
|                 |              | $10^6$                | $1.2^*$           |
|                 |              | $10^7$                | $0.12^*$          |


37/39

**Figure 8**

38/39

**Figure 9**

39/39

**Figure 10**

SUBSTITUTE SHEET (RULE 26)

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- BLACK BORDERS**
- IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- FADED TEXT OR DRAWING**
- BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- SKEWED/SLANTED IMAGES**
- COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- GRAY SCALE DOCUMENTS**
- LINES OR MARKS ON ORIGINAL DOCUMENT**
- REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- OTHER:** \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**